

Supporting Information

Metal-free transfer hydrogenation/cycloaddition cascade of activated quinolines and isoquinolines with tosyl azides

Suman Yadav,^a Ruchir Kant^b and Malleswara Rao Kuram^{a,c*}

^aMedicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India

^bMSB Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India

^cAcademy of Scientific & Innovative Research (AcSIR), Ghaziabad 201002, India

Email: malleswara.kuram@cdri.res.in

TABLE OF CONTENTS

1	General Information/Analytical Methods/Materials	S2
2	Preparation of starting materials	S3
3	General Procedure	S6
4	Optimization of reaction conditions	S6
5	Characterization data	S10
6	Applications and synthetic transformations	S24
7	Control experiments	S29
8	Crystal Structure	S40
9	Reference	S41
10	Copies of Spectra	S43

1. General Information:

Unless otherwise noted, all the reactions were performed using oven-dried Schlenk tubes under nitrogen. The reactions were monitored by Merck silica gel 60 F₂₅₄ precoated plates (0.25 mm) visualizing under UV light (254 nm) or I₂ staining. Temperature mentioned for any reaction is corresponding to the oil bath temperature. Column chromatography was performed using silica gel 60-120 Å or 100-200 Å mesh of Merck Company.

2. Analytical Methods:


¹H, ¹³C, and ¹⁹F nuclear magnetic resonance spectra were recorded on Bruker Advance III 400 MHz spectrometer at 25 °C. NMRs of the products were measured in CDCl₃. The chemical shifts in ¹H NMR and ¹³C{¹H} NMR spectra are reported in parts per million (ppm) and are referenced to the residual solvent signal as the internal standard; ¹H NMR spectra (CDCl₃: δ 7.26 ppm) and ¹³C (CDCl₃: δ 77.16). The coupling constant (J) was reported in Hertz (Hz). Splitting patterns are denoted as "s" for singlet; "d" for doublet; "t" for triplet; "q" for quartet; "sext" for sextet; "sept" for septet; "m" for multiplet, "br" for broad; "dt" for doublet of triplets; "td" for triplet of doublets. ESI-HRMS were recorded on AGILENT 6520 Q-TOF spectrometer.

3. Materials:

All commercially available chemicals were used as received unless otherwise indicated. The quinoline, isoquinoline, and azide substrates were purchased from GLR Innovations/TCI and used without further purification. 7-Methyl quinoline was purchased from TCI Chemicals, containing 25% 5-methyl quinoline at maximum. 6-phenyl quinoline and 5-phenyl quinoline are prepared in the lab according to literature procedures.¹ Pregnenolone and Isopulegol derived quinoline were prepared in the lab, and the detailed procedures are described here. Formic acid-d₂ was purchased from Sigma-Aldrich.


4. Preparation of Starting materials:

4.1. Preparation of 6-phenyl and 5-phenyl quinoline:¹




A mixture of 6-Bromo-quinoline or 5-Bromo-quinoline (312 mg, 1.5 mmol, 1 equiv.), sodium carbonate (635 mg, 4 equiv.), phenylboronic acid (219 mg, 1.2 equiv.), water (2 mL), toluene (2 mL) and ethanol (1 mL) was degassed by nitrogen bubbling, then Pd(PPh₃)₄ (87 mg, 5 mol%) was added, and the mixture was heated to 80 °C for 12 hours. After the completion of the reaction, the mixture was filtered through a plug of Celite, and the filtrate was diluted with water (20 mL) and extracted with CH₂Cl₂ (3 x 10 mL). The combined organic extracts were washed with brine (20 mL) and dried over Na₂SO₄. The drying agent was filtered off, and the solvent was evaporated. The residue was purified by column chromatography (silica, Hexane:EtOAc 4:1). 6-Phenyl quinoline was obtained in 81% yield, and 5-Phenyl-quinoline was obtained in 92% yield.

4.2. Preparation of N-(quinolin-6-yl)benzamide:²




In a round-bottom flask was taken 6-amino-quinoline (300 mg, 2.1 mmol, 1.0 equiv.) and Et₃N (1.2 equiv.) under a nitrogen atmosphere, and 4-5 mL DCM was added and cooled to 0 °C. To this, PhCOCl (1.2 equiv.) was added dropwise with stirring. The reaction mixture was allowed to warm to room temperature and stirred for 18 h. The reaction mixture was then diluted with DCM and quenched with a saturated solution of NaHCO₃, and the resulting mixture was extracted twice with CH₂Cl₂. The combined organic layer was washed with brine and dried over anhydrous Na₂SO₄, filtered, and concentrated under vacuum. The crude product was purified by silica gel column chromatography (silica, 2% MeOH/DCM) furnishing N-(quinolin-6-yl)benzamide (477 mg, 92% yield) as yellow solid.

4.3. Preparation of Pregnenolone and Isopulegol-derived quinoline




To a suspension of a₉ (807 mg, 1.2 equiv) in CH₂Cl₂ was added 4-(dimethylamino)-pyridine (DMAP, 2.5 equiv.) in one portion at room temperature and the reaction mixture was stirred for 10 min. To this was added N-(3-(Dimethylamino)propyl)-N'-ethylcarbodiimide hydrochloride (EDC, 1.2 equiv) at 0 °C and the

resultant suspension was stirred for 10 min. Then, a solution of **a**₁₀ (600 mg, 3.88 mmol) in CH₂Cl₂ was added. The cooling bath was removed after the completion of the addition, and the reaction mixture was stirred at room temperature for 16 h. The solution was diluted by the addition of saturated aqueous NH₄Cl solution and CH₂Cl₂ at room temperature. The organic phase was dried with anhydrous Na₂SO₄, and then concentrated by removing the solvent under vacuum. Finally, the residue was purified by silica gel column chromatography (silica, 1:4 EtOAc/Hexane) to yield **a**₁₁ (850 mg, 71%) as yellow oil. ¹H NMR (400 MHz, CDCl₃): δ 8.99 (dd, *J* = 4.2, 1.7 Hz, 1H), 8.54 (d, *J* = 1.7 Hz, 1H), 8.28 – 8.24 (m, 2H), 8.13 (d, *J* = 8.8 Hz, 1H), 7.45 (dd, *J* = 8.3, 4.2 Hz, 1H), 5.10 (td, *J* = 10.9, 4.4 Hz, 1H), 4.83 (s, 1H), 4.73 – 4.72 (m, 1H), 2.39 – 2.32 (m, 1H), 2.23 – 2.18 (m, 1H), 1.83 – 1.77 (m, 2H), 1.72 (s, 3H), 1.69 – 1.61 (m, 1H), 1.55 – 1.47 (m, 1H), 1.25 – 1.17 (m, 1H), 1.06 – 1.02 (m, 1H), 0.98 (d, *J* = 6.5 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 165.6, 152.4, 150.1, 146.2, 137.4, 130.9, 129.7, 129.2, 128.9, 127.5, 121.8, 112.2, 74.9, 51.1, 40.6, 34.3, 31.6, 30.5, 22.2, 19.6. HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₂₀H₂₄NO₂ 310.1807; found 310.1799.



To a suspension of **a**₁₂ (1.2 mmol) in CH₂Cl₂ was added DMAP (4- (dimethylamino)-pyridine, 2.5 mmol) in one portion at room temperature and the reaction mixture was stirred for 10 min. To this was added N-(3-(Dimethylamino)propyl)-N'-ethylcarbodiimide hydrochloride (EDC, 1.2 mmol) at 0 °C and the resultant suspension was stirred for 10 min. A solution of **a**₁₃ (316 mg, 1.0 mmol) in CH₂Cl₂ was then added at 0 °C, and the cooling bath was removed, and the reaction mixture was stirred at room temperature for 16 h. The solution was diluted by the addition of saturated aqueous NH₄Cl solution and CH₂Cl₂ at room temperature. The organic phase was dried with anhydrous Na₂SO₄, and then concentrated by removing the solvent under vacuum. Finally, the residue was purified by silica gel column chromatography (silica, 2:3 EtOAc/Hexane) to furnish **a**₁₄ (350 mg, 84%) as a white solid. ¹H NMR (400 MHz, CDCl₃): δ 9.00 (dd, *J* = 4.2, 1.7 Hz, 1H), 8.58 (d, *J* = 1.7 Hz, 1H), 8.31 (dd, *J* = 8.8, 1.9 Hz, 1H), 8.27 (dd, *J* = 8.3, 1.1 Hz, 1H), 8.14 (d, *J* = 8.8 Hz, 1H), 7.47 (dd, *J* = 8.3, 4.2 Hz, 1H), 5.44 (d, *J* = 3.9 Hz, 1H), 4.98 – 4.89 (m, 1H), 2.57 – 2.52 (m, 3H), 2.13 (s, 3H), 2.08 – 1.93 (m, 5H), 1.86 – 1.78 (m, 2H), 1.71 – 1.61 (m, 4H), 1.53 – 1.46 (m, 3H), 1.29 – 1.28 (m, 1H), 1.23 – 1.15 (m, 2H), 1.09 (s, 3H), 0.65 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 209.6, 165.6, 152.2, 150.1, 139.7, 137.4, 130.9, 129.8, 129.2, 128.9, 127.5, 122.7, 121.9, 75.1, 63.8, 56.9, 50.0, 44.1, 38.9, 38.3, 37.2, 36.8, 31.9, 31.9, 31.7, 28.0, 24.6, 22.9, 21.2, 19.5, 13.3. HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₃₁H₃₈NO₃ 472.2852; found 472.2842. Melting Point: 234-235 °C


4.4. Preparation of (E)-5-styrylisoquinoline:³



A 50 mL round-bottomed flask containing a stirring bar was sequentially charged under nitrogen with PdCl₂(PPh₃)₂ (35.0 mg, 5 mol%), 5-Br-isoquinoline (**a**₁₅, 208 mg, 1.0 mmol), **a**₁₆ (156 mg, 1.5 eq), and K₂CO₃ (483 mg, 3.5 eq), in dry DMF (4 mL), and the round-bottom flask was sealed and set in an oil bath at 160 °C


for 24 h. When the reaction was complete, the crude reaction mixture was allowed to reach room temperature. Then, 50 mL of EtOAc was added, and the mixture was filtered under gravity and the solid residue was washed with EtOAc (3 x 5 mL). The solvent was removed under reduced pressure. Finally, the reaction mixture was purified by silica gel column chromatography (1:9 EtOAc/hexane mixtures) obtaining the desired product **a**₁₇ (207 mg, 89 %) as a brown oil. **¹H NMR (500 MHz, CDCl₃):** δ 9.25 (s, 1H), 8.56 (d, *J* = 6.0 Hz, 1H), 7.97 (d, *J* = 6.0 Hz, 1H), 7.94 (d, *J* = 7.2 Hz, 1H), 7.89 (d, *J* = 8.1 Hz, 1H), 7.75 (d, *J* = 16.0 Hz, 1H), 7.62 – 7.58 (m, 3H), 7.40 (t, *J* = 7.6 Hz, 2H), 7.33 – 7.30 (m, 1H), 7.18 (d, *J* = 16.0 Hz, 1H). **¹³C{¹H} NMR (125 MHz, CDCl₃):** δ 153.2, 143.3, 137.2, 134.2, 134.1, 132.9, 129.1, 128.9, 128.3, 127.5, 127.4, 127.2, 126.9, 123.9, 116.8. HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₇H₁₄N 232.1126; found 232.1119.

4.5. Preparation of 4-(isoquinolin-4-yl)butan-2-one³ :



In a 25 mL round-bottomed flask containing a stirring bar, isoquinoline (500 mg, 3.87 mmol, 1.0 equiv.), benzoic acid (1.42 g, 3.0 equiv.), vinyl ketone (1.08 g, 4.0 equiv.), and MeCN (6.0 mL) were added, and the flask was placed in a pre-heated oil bath at 90 °C for 24 h. The reaction mixture was diluted in CH₂Cl₂ and quenched with K₂CO₃ solution. The layers were separated, and the aqueous phase was further extracted with CH₂Cl₂. The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (5/95% MeOH/DCM) to furnish **a**₂₀ (560 mg, 73%) as a brown oil.


4.6. General Procedure A for the Preparation of Sulfonyl Azides:⁴



To the solution of NaN₃ (1.5 equiv) in water (0.5 mL) was added a solution of sulfonyl chloride (1.0 mmol, 1.0 equiv) in acetone (1 mL) at 0 °C dropwise. The reaction mixture was warmed up to room temperature and stirred for 12 h. Acetone was removed under reduced pressure and the reaction mixture was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄ and the solvent was removed under reduced pressure. The crude product was used without further purification.

Caution! Organic azides are potentially explosive substances (initial temperature of the explosive decomposition is about 120 °C) that can and will decompose with the slightest input of energy from external sources (heat, light, pressure) and should be handled with great care. They should not be heated too much when concentrating. They should be stored at low temperature in a refrigerator.

4.7. General Procedure B for the synthesis of quinolinium and isoquinolinium salts:^{5a-5h}




A mixture of the corresponding quinoline/isoquinoline (1.0 equiv.) and alkyl halide (1.2 equiv.) in CH₃CN/1,4-dioxane was refluxed for 24-30 h. The solvent was removed under reduced pressure. The resulting precipitate was washed with diethyl ether and dried under vacuum to give the desired quinolinium and isoquinolinium salts.

- Acetonitrile was used as a solvent for **1a-1n**, **1r-1z**, **4a-4n**.
- 1,4-Dioxane was used as a solvent for **1o** and **1p**.
- Neat reaction was performed for **1q**.

5. General Procedure C for the Synthesis of Cyclic Amidines

An oven-dried Schlenk tube was charged with quinolinium/isoquinolinium salt (**1/4**, 0.3 mmol, 1.0 equiv.) and organic azide (**2**, 0.6 mmol, 2.0 equiv.), and exchanged with nitrogen and vacuum three times. To this was added Et₃N (85 μL, 2.0 equiv.) and MeCN (3 mL) followed by the addition of HCOOH (56 μL, 5.0 equiv.), and the reaction mixture was heated to 80 °C for 16 hours. The reaction was cooled after the completion of the reaction (monitored by TLC), diluted with EtOAc, and quenched with an aqueous K₂CO₃ solution. The organic phase was separated, and the aqueous phase was extracted with EtOAc. The combined organic phase was washed with H₂O and dried over Na₂SO₄. The solvent was removed under reduced pressure. The resulting residue was purified by column chromatography on silica gel (PE/EA = 4:1 to 1:1) to give the corresponding cyclic amidine product **3/5**.

6. Optimization of reaction conditions:




Entry	Azide (2 equiv)	HCOOH	NEt ₃	Solvent	Temp.	Yield (%) of 3a	Yield (%) of 3a'	Yield (%) of 3a''
1	TsN ₃	5 equiv.	2 equiv.	CH ₃ CN	80 °C	78(72)	trace	n.d.
2	DPPA	"	"	"	"	n.d.	n.d.	n.d.
3	TMSA	"	"	"	"	n.d.	n.d.	n.d.
4	TsN ₃	"	"	neat	"	48	trace	n.d.
5	"	"	"	DCE	"	70	trace	n.d.
6	"	"	"	THF	"	72	trace	n.d.


7	"	"	"	MeOH	"	14	trace	n.d.
8	"	"	"	Toluene	"	74	trace	n.d.
9	"	"	"	CF ₃ -Toluene	"	40	trace	n.d.
10	"	"	"	DMF	"	60	trace	n.d.
11	"	"	"	CH ₃ CN	90	72	trace	n.d.
12	(1.5 equiv)	"	"	"	90	72	trace	n.d.
13	(2.0 equiv)	"	"	"	60	50	trace	n.d.
14	"	"	"	THF	"	60	trace	n.d.
15	"	2 equiv.	5 equiv.	CH ₃ CN	90	66	trace	n.d.
16	"	2 equiv.	2 equiv.	"	"	72	trace	n.d.
17	"	8 equiv.	2 equiv.	"	"	44	trace	n.d.
18	"	5 equiv.	-	"	80	n.d.	trace	n.d.
19	"	-	2 equiv.	"	80	n.d.	n.d.	60
20 ^c	"	-	-	EtOH	90	28	n.d.	15
21 ^d	"	-	-	CH ₃ CN	80	72	trace	n.d.
22 ^e	"	"	-	"	"	61	trace	n.d.
23 ^f	"	"	-	"	"	62	trace	n.d.
24	-	"	"	"	"	n.d.	53	n.d.

^aReaction conditions: **1a** (1.0 equiv.), **2a** (2.0 equiv.), HCOOH (5.0 equiv.), NEt₃ (2.0 equiv.) at 80 °C for 16 h. ¹H NMR yield using 1,3,5-trimethoxybenzene as internal standard. n.d. = not detected. ^bIsolated yield in parenthesis. ^c[IrCp*Cl₂]₂ (1.0 mol%), PhCONHOMe (2.0 mol%), KI (3.0 equiv.), DABCO (1.0 equiv.), ethanol, 90 °C. ^dHCOONH₄ (5.0 equiv) as a hydrogen source. ^e DIPEA base (2.0 equiv.). ^fDABCO base (2.0 equiv.). DPPA = Diphenylphosphoryl azide, TMSA = Trimethylsilyl azide, DIPEA = N,N-Diisopropylethylamine, DABCO = (1,4-diazabicyclo[2.2.2]octane), DCE = 1,2-dichloroethane, THF = Tetrahydrofuran


7. Substrates employed in the reaction:




1a




1b




1c




1d




1e




1f




1g




1h




1i




1j




1k




1l




1m




1n




1o




1p




1q




1r




1s




1t




1u




1v




1w




1x




1y




1z




4a




4b




4c




4d




4e




4f




4a''




4g




4h




4i




4j




4k




4l




4m




4n




4o




4p




4q




4r






4s



4t




4u




8. Characterization data of Starting materials

1-benzyl-6-phenylquinolin-1-ium bromide (1f):




The representative general procedure **B** was followed, using 6-Phenyl quinoline (250 mg, 1.2 mmol) under reflux for 24 h to afford **1f** (380 mg, 84%) as a hygroscopic yellow solid. **¹H NMR (400 MHz, DMSO-*d*₆)**: δ 9.76 (s, 1H), 9.40 (d, *J* = 8.4 Hz, 1H), 8.86 (s, 1H), 8.61–8.55 (m, 2H), 8.34 – 8.31 (m, 1H), 7.92 (d, *J* = 7.5 Hz, 2H), 7.61 – 7.57 (m, 2H), 7.53– 7.49 (m, 1H), 7.43 – 7.38 (m, 5H), 6.43 (s, 2H). **¹³C{¹H} NMR (100 MHz, DMSO-*d*₆)**: δ 150.1, 148.1, 141.0, 137.0, 136.9, 134.5, 133.9, 130.5, 129.3, 129.1, 128.8, 127.5, 127.4, 127.2, 122.8, 119.9, 59.9. **HRMS (ESI) m/z**: [M-Br]⁺ calcd for C₂₂H₁₈N 296.1434; found 296.1445.

6-benzamido-1-benzylquinolin-1-ium bromide (1h):




The representative general procedure **B** was followed, using N-(quinolin-6-yl)benzamide (250 mg, 1.0 mmol) and benzyl bromide (1.2 equiv.) under reflux for 24 h to afford **1h** (377 mg, 90%) as a yellow solid. **¹H NMR (400 MHz, DMSO-*d*₆)**: δ 10.98 (s, 1H), 9.65 (dd, *J* = 5.8, 1.1 Hz, 1H), 9.36 (d, *J* = 8.4 Hz, 1H), 9.05 (d, *J* = 2.3 Hz, 1H), 8.58 (d, *J* = 9.6 Hz, 1H), 8.44 (dd, *J* = 9.6, 2.4 Hz, 1H), 8.24 (dd, *J* = 8.4, 5.7 Hz, 1H), 8.06 – 8.03 (m, 2H), 7.68 – 7.64 (m, 1H), 7.61 – 7.57 (m, 2H), 7.41 – 7.36 (m, 5H), 6.38 (s, 2H). **¹³C{¹H} NMR (100 MHz, DMSO-*d*₆)**: δ 166.4, 148.3, 147.3, 139.9, 134.2, 133.9, 133.8, 132.2, 130.9, 129.6, 129.1, 128.7, 128.5, 127.9, 127.3, 122.6, 120.0, 117.3, 59.7. **HRMS (ESI) m/z**: [M-Br]⁺ calcd for C₂₃H₁₉N₂O 339.1497; found 339.1499. Melting Point: 252-253 °C.

1-benzyl-5-phenylquinolin-1-ium bromide (1k):




The representative general procedure **B** was followed, using 5-Phenyl quinoline (250 mg, 1.2 mmol) under reflux for 24 h to afford **1k** (350 mg, 76%) as a hygroscopic yellow solid. **¹H NMR (400 MHz, DMSO-*d*₆)**: δ 9.96 – 9.91 (m, 1H), 9.03 (d, *J* = 8.5 Hz, 1H), 8.59 (d, *J* = 8.9 Hz, 1H), 8.28– 8.23 (m, 2H), 7.95 (d, *J* = 7.1 Hz, 1H), 7.64 – 7.55 (m, 5H), 7.47– 7.35 (m, 5H) 6.50 (s, 2H). **¹³C{¹H} NMR (100 MHz, DMSO-*d*₆)**: δ 150.3, 145.9, 142.5, 138.1, 136.7, 135.1, 133.9, 130.5, 130.2, 129.1, 128.9, 128.8, 128.7, 128.2, 127.3, 122.6, 118.7, 60.3. **HRMS (ESI) m/z**: [M-Br]⁺ calcd for C₂₂H₁₈N 296.1434; found 296.1436.

1-pentylquinolin-1-ium bromide (1q):



The representative general procedure **B** was followed, using quinoline (250 mg, 1.9 mmol) and pentyl bromide (1.2 equiv.) under reflux for 24 h to afford **1q** (531 mg, 98%) as a sticky white solid. **¹H NMR (400 MHz, DMSO-*d*₆)**: δ 9.70 (dd, *J* = 5.8, 1.3 Hz, 1H), 9.35 (d, *J* = 8.3 Hz, 1H), 8.66 (d, *J* = 8.9 Hz, 1H), 8.53 (dd, *J* = 8.2, 1.3 Hz, 1H), 8.31– 8.26 (m, 1H), 8.22 (dd, *J* = 8.3, 5.8 Hz, 1H), 8.08 – 8.04 (m, 1H), 5.14 – 5.09 (m, 2H), 2.01– 1.93 (m, 2H), 1.42 – 1.27 (m, 4H), 0.85 (t, *J* = 7.1 Hz, 3H). **¹³C{¹H} NMR (100 MHz, DMSO-*d*₆)**: δ 149.6, 147.3, 137.3, 135.6, 130.7, 129.8, 129.6, 122.1, 118.9, 57.2, 29.2, 27.8, 21.6, 13.7. **HRMS (ESI) m/z**: [M-Br]⁺ calcd for C₁₄H₁₈N 200.1439; found 200.1431.


1-allylquinolin-1-ium bromide (1r):



The representative general procedure **B** was followed, using quinoline (250 mg, 1.9 mmol) and allyl bromide (1.2 equiv.) under reflux for 24 h to afford **1r** (458 mg, 95%) as a white solid. **¹H NMR (400 MHz, DMSO-*d*₆)**: δ 9.76 – 9.72 (m, 1H), 9.40 (d, *J* = 8.3 Hz, 1H), 8.59 –


8.53 (m, 2H), 8.29 – 8.25 (m, 2H), 8.07 – 8.03 (m, 1H), 6.28 – 6.19 (m, 1H), 5.84 – 5.83 (m, 2H), 5.41– 5.33 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6): δ 149.8, 147.7, 137.5, 135.5, 131.3, 130.6, 129.8, 129.6, 122.3, 120.4, 119.2, 58.9. HRMS (ESI) m/z : $[\text{M-Br}]^+$ calcd for $\text{C}_{12}\text{H}_{12}\text{N}$ 170.0970; found 170.0962. Melting Point: 160-165 °C.

1-(4-nitrobenzyl)quinolin-1-ium bromide (1t):




The representative general procedure **B** was followed, using quinoline (250 mg, 1.9 mmol) and 4-nitro benzyl bromide (1.2 equiv.) under reflux for 24 h to afford **1t** (646 mg, 97%) as a white solid. ^1H NMR (400 MHz, DMSO- d_6): δ 9.93 (d, J = 5.5 Hz, 1H), 9.48 (d, J = 8.3 Hz, 1H), 8.57 (d, J = 8.2 Hz, 1H), 8.45 (d, J = 8.9 Hz, 1H), 8.39 – 8.35 (m, 1H), 8.23 – 8.19 (m, 3H), 8.06 – 8.02 (m, 1H), 7.65 (d, J = 8.5 Hz, 2H), 6.64 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6): δ 150.9, 148.6, 147.4, 141.2, 137.5, 135.9, 130.9, 130.0, 129.9, 128.5, 123.9, 122.6, 119.1, 59.0. HRMS (ESI) m/z : $[\text{M-Br}]^+$ calcd for $\text{C}_{16}\text{H}_{13}\text{N}_2\text{O}_2$ 265.0977; found 265.0976. Melting Point: 219-220 °C.

1-(3-bromobenzyl)quinolin-1-ium bromide (1v):




The representative general procedure **B** was followed, using quinoline (250 mg, 1.9 mmol) and 3-bromo benzyl bromide (1.2 equiv.) under reflux for 24 h to afford **1v** (648 mg, 99%) as a white solid. ^1H NMR (400 MHz, DMSO- d_6): δ 9.85 (d, J = 5.8 Hz, 1H), 9.43 (d, J = 8.3 Hz, 1H), 8.56 – 8.52 (m, 2H), 8.32 (dd, J = 8.4, 5.8 Hz, 1H), 8.26 – 8.22 (m, 1H), 8.05 – 8.02 (m, 1H), 7.76 (s, 1H), 7.58 – 7.55 (m, 1H), 7.39 – 7.32 (m, 2H), 6.44 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6): δ 150.7, 148.3, 137.4, 136.4, 135.8, 131.7, 131.1, 130.9, 130.2, 129.9, 129.8, 126.4, 122.5, 122.2, 119.1, 58.9. HRMS (ESI) m/z : $[\text{M-Br}]^+$ calcd for $\text{C}_{16}\text{H}_{13}\text{BrN}$ 298.0231; found 298.0226. Melting Point: 175-176 °C.

1-(3-(trifluoromethyl)benzyl)quinolin-1-ium bromide (1w):



The representative general procedure **B** was followed, using quinoline (250 mg, 1.9 mmol) and 1-(bromomethyl)-3-(trifluoromethyl)benzene (1.2 equiv.) under reflux for 24 h to afford **1w** (750 mg, 99%) as a white solid. ^1H NMR (400 MHz, D_2O): δ 9.35 (d, J = 5.7 Hz, 1H), 9.15 (d, J = 8.4 Hz, 1H), 8.29 (d, J = 8.2 Hz, 1H), 8.24 (d, J = 9.0 Hz, 1H), 8.09 – 8.02 (m, 2H), 7.90 – 7.86 (m, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.59 (s, 1H), 7.52 – 7.45 (m, 2H), 6.30 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, D_2O): δ 149.4, 148.8, 137.9, 136.2, 133.8, 130.9, 130.7 (d, J = 32.9 Hz), 130.3, 130.1, 130.0, 125.9 (d, J = 3.5 Hz), 123.9 (d, J = 3.5 Hz), 123.5 (d, J = 271.7 Hz), 121.9, 118.4, 60.3. ^{19}F NMR (376 MHz, CDCl_3): δ - 62.58. HRMS (ESI) m/z : $[\text{M-Br}]^+$ calcd for $\text{C}_{17}\text{H}_{13}\text{F}_3\text{N}$ 288.0995; found 288.0996. Melting Point: 211-212 °C.


1-benzyl-6-(((5-methyl-2-(prop-1-en-2-yl)cyclohexyl)oxy)carbonyl)quinolin-1-ium bromide (1y):



The representative general procedure **B** was followed, using **a**₁₁ (300 mg, 0.97 mmol) and benzyl bromide (1.2 equiv.) under reflux for 48 h to afford **1y** (325 mg, 70%) as a sticky brown solid. ^1H NMR (400 MHz, $\text{CD}_3\text{OD-}d_4$): δ 9.69 (d, J = 5.8, 1H), 9.47 (d, J = 8.3 Hz, 1H), 9.06 (s, 1H), 8.64 (s, 2H), 8.29 (dd, J = 8.3, 5.8 Hz, 1H), 7.47 – 7.39 (m, 5H), 6.43 (s, 2H), 5.16 (dt, J = 10.9, 4.4 Hz, 1H), 4.69 – 4.68 (m, 1H), 2.45 – 2.38 (m, 1H), 2.17 – 2.13 (m, 1H), 1.84 – 1.75 (m, 2H), 1.71 (s, 3H), 1.68 – 1.62 (m, 1H), 1.31 – 1.28 (m, 4H), 1.01 (d, J = 6.5 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CD_3OD): δ 164.8, 152.6, 151.0, 147.3, 141.4, 135.9, 134.1, 133.9, 133.2, 131.5, 130.6, 130.5, 128.8, 124.3, 121.2,

112.9, 76.9, 62.4, 52.3, 41.4, 35.1, 32.7, 31.4, 22.4, 19.6. HRMS (ESI) m/z : $[M-Br]^+$ calcd for $C_{27}H_{30}NO_2$ 400.2271; found 400.2268. HRMS (ESI) m/z : $[M-Br]^+$ calcd for $C_{27}H_{30}NO_2$ 400.2271; found 400.2268.


6-(((3S,3aS,9R,11aS)-3-acetyl-3a,11a-dimethyl-2,3,3a,4,5,5a,6,8,9,10,11,11a,11b,11c-tetradecahydro-1H-cyclopenta[c]phenanthren-9-yl)oxy)carbonyl)-1-benzylquinolin-1-ium bromide (1z):



The representative general procedure **B** was followed, using **a14** (300 mg, 0.64 mmol) and benzyl bromide (1.2 equiv.) under reflux for 48 h to afford **1z** (308 mg, 75%) as an off white solid. 1H NMR (400 MHz, CD_3OD-d_4): δ 9.65 (d, $J = 5.8$, 1H), 9.45 (d, $J = 8.3$ Hz, 1H), 9.11 (d, $J = 1.6$ Hz, 1H), 8.69 – 8.61 (m, 2H), 8.27 (dd, $J = 8.3$, 5.9 Hz, 1H), 7.47 – 7.37 (m, 5H), 6.40 (s, 2H), 5.46 (d, $J = 4.9$ Hz, 1H), 2.71 – 2.63 (m, 1H), 2.58 – 2.49 (m, 2H), 2.17 – 2.11 (m, 4H), 2.10 – 1.98 (m, 4H), 1.91 – 1.84 (m, 1H), 1.75 – 1.61 (m, 4H), 1.58 – 1.48 (m, 3H), 1.30 – 1.16 (m, 4H), 1.12 – 1.06 (m, 4H), 0.64 (s, 3H). $^{13}C\{^1H\}$ NMR (100

MHz, CD_3OD-d_4): δ 212.3, 164.9, 152.6, 151.0, 141.4, 140.7, 136.1, 134.1, 134.0, 133.3, 131.6, 130.6, 130.5, 128.8, 124.2, 123.9, 121.0, 77.4, 64.6, 62.4, 57.9, 51.4, 45.1, 39.8, 39.0, 38.2, 37.8, 33.1, 32.9, 31.6, 28.7, 25.4, 23.8, 22.2, 19.7, 13.6. HRMS (ESI) m/z : $[M-Br]^+$ calcd for $C_{38}H_{44}BrNO_3$ 562.3316; found 562.3317. Melting Point: 210-211 °C.


(E)-2-benzyl-5-styrylisoquinolin-2-ium bromide (4f):



The representative general procedure **B** was followed, using (E)-5-styrylisoquinoline (200 mg, 0.86 mmol) and benzyl bromide (1.2 equiv.) under reflux for 24 h to afford **4f** (294 mg, 85%) as a yellow solid. 1H NMR (400 MHz, $DMSO-d_6$): δ 10.39 (s, 1H), 9.11 (d, $J = 6.9$ Hz, 1H), 8.95 (d, $J = 6.7$ Hz, 1H), 8.62 (d, $J = 7.3$ Hz, 1H), 8.46 (d, $J = 8.0$ Hz, 1H), 8.09 – 8.06 (m, 2H), 7.82 (d, $J = 7.4$ Hz, 2H),

7.65 (d, $J = 6.6$ Hz, 2H), 7.54 (d, $J = 16.1$ Hz, 1H), 7.45 – 7.29 (m, 6H), 6.04 (s, 2H). $^{13}C\{^1H\}$ NMR (100 MHz, $DMSO-d_6$): δ 150.2, 136.3, 134.5, 134.4, 134.3, 134.2, 132.5, 131.1, 129.8, 129.1, 128.9, 128.6, 128.5, 128.4, 127.9, 127.2, 123.1, 121.5, 62.8. HRMS (ESI) m/z : $[M-Br]^+$ calcd for $C_{24}H_{20}N$ 322.1596; found 322.1587.


2-(2-nitrobenzyl)isoquinolin-2-ium bromide (4g):



The representative general procedure **B** was followed, using Isoquinoline (250 mg, 1.9 mmol) and 2-nitro benzyl bromide (1.2 equiv.) under reflux for 24 h to afford **4g** (653 mg, 98%) as a white solid. 1H NMR (400 MHz, $DMSO-d_6$): δ 10.24 (s, 1H),

8.82 (d, $J = 6.5$ Hz, 1H), 8.70 (d, $J = 6.8$ Hz, 1H), 8.58 (d, $J = 8.3$ Hz, 1H), 8.43 (d, $J = 8.3$ Hz, 1H), 8.34 – 8.28 (m, 2H), 8.13 – 8.09 (m, 1H), 7.83 – 7.74 (m, 2H), 7.34 (d, $J = 7.4$ Hz, 1H), 6.42 (s, 2H). $^{13}C\{^1H\}$ NMR (100 MHz, $DMSO-d_6$): δ 151.0, 147.6, 137.3, 137.2, 135.2, 134.9, 131.3, 130.9, 130.8, 130.5, 129.0, 127.3, 127.2, 126.1, 125.5, 60.5. HRMS (ESI) m/z : $[M-Br]^+$ calcd for $C_{16}H_{13}N_2O_2$ 265.0977; found 265.0967. Melting Point: 223-224 °C.


2-(3-bromobenzyl)isoquinolin-2-ium bromide (4h):



The representative general procedure **B** was followed, using Isoquinoline (250 mg, 1.9 mmol) and 3-bromo benzyl bromide (1.2 equiv.) under reflux for 24 h to afford **4h** (648 mg, 99%) as a white solid. 1H NMR (400 MHz, $DMSO-d_6$): δ 10.46 (s, 1H), 8.93 – 8.91 (m, 1H), 8.64 (d, $J = 6.8$ Hz, 1H), 8.55 (d, $J = 8.3$ Hz, 1H), 8.37 (d, $J = 8.3$ Hz, 1H),

8.29 – 8.25 (m, 1H), 8.11 – 8.07 (m, 1H), 7.96 – 7.95 (m, 1H), 7.68 (dd, $J = 7.6, 0.7$ Hz, 1H), 7.62 (d, $J = 7.9$ Hz, 1H), 7.41 (t, $J = 7.9$ Hz, 1H), 6.06 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6): δ 150.4, 137.1, 137.0, 136.6, 134.6, 132.1, 131.7, 131.2, 131.1, 130.6, 128.1, 127.2, 127.2, 126.2, 122.1, 62.1. HRMS (ESI) m/z : $[\text{M}-\text{Br}]^+$ calcd for $\text{C}_{16}\text{H}_{13}\text{BrN}$ 298.0231; found 298.0228. Melting Point: 220-222 °C.

2-benzyl-4-(3-oxobutyl)isoquinolin-2-ium bromide (4n):




The representative general procedure **B** was followed, using 4-(isoquinolin-4-yl)butan-2-one (200 mg, 1.0 mmol) and benzyl bromide (1.2 equiv.) under reflux for 24 h to afford **4n** (315 mg, 85%) as a yellow solid. ^1H NMR (400 MHz, DMSO- d_6): δ 10.26 (s, 1H), 8.85 (s, 1H), 8.55 (d, $J = 8.2$ Hz, 1H), 8.44 (d, $J = 8.5$ Hz, 1H), 8.29 (t, $J = 7.5$ Hz, 1H), 8.10 – 8.07 (m, 1H), 7.64 – 7.62 (m, 2H), 7.47 – 7.40 (m, 3H), 5.99 (s, 2H), 3.36 (t, $J = 7.3$ Hz, 2H), 3.01 (t, $J = 7.3$ Hz, 2H), 2.14 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$

NMR (100 MHz, DMSO- d_6): δ 206.5, 148.4, 138.1, 137.1, 136.0, 134.4, 133.4, 131.3, 131.0, 129.2, 129.1, 128.8, 127.2, 124.1, 63.1, 41.9, 29.7, 23.2. HRMS (ESI) m/z : $[\text{M}-\text{Br}]^+$ calcd for $\text{C}_{20}\text{H}_{20}\text{BrNO}$ 290.1539; found 290.1549. Melting Point: 179-180 °C.

9. Characterization data of isolated products


(E)-N-(1-benzyl-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3a):



Prepared according to the general procedure **C** from 1-benzylquinolin-1-ium bromide (**1a**) (90 mg, 0.3 mmol). Flash column chromatography (22-22% EtOAc/Hex) afforded the desired product **3a** as a yellow solid (84 mg, 0.21 mmol, 72% yield). Reaction time: 19 h. Reaction temperature: 80 °C. Melting point: 140-142 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). ^1H

NMR (400 MHz, CDCl_3): δ 7.61 (d, $J = 8.3$ Hz, 2H), 7.31 – 7.24 (m, 3H), 7.19 – 7.12 (m, 6H), 7.06 – 7.02 (m, 1H), 6.97 (d, $J = 8.1$ Hz, 1H), 5.25 (s, 2H), 3.45 – 3.41 (m, 2H), 2.95 – 2.91 (m, 2H) 2.36 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.8, 142.3, 140.4, 138.8, 136.0, 129.1, 128.8, 127.9, 127.8, 127.3, 127.2, 126.3, 124.5, 116.8, 49.6, 28.0, 24.0, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O}_2\text{S}$ 391.1480; found 391.1497. The analytical data of the compound are in accordance with the literature.⁶


(E)-N-(1-benzyl-6-methyl-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3b):



Prepared according to the general procedure **C** from 1-benzyl-6-methylquinolin-1-ium bromide (**1b**) (94 mg, 0.3 mmol). Flash column chromatography (20-22% EtOAc/Hex) afforded the desired product **3b** as a white solid (92 mg, 0.23 mmol, 76% yield). Reaction time: 18 h. Reaction temperature: 80 °C. Melting point: 128-130 °C. $R_f = 0.3$

(EtOAc/Hex 3:7). ^1H NMR (400 MHz, $\text{CD}_3\text{OD} + \text{CDCl}_3$): δ 7.57 (d, $J = 7.9$ Hz, 2H), 7.29 – 7.21 (m, 5H), 7.13 (d, $J = 7.2$ Hz, 2H), 7.03 (s, 1H), 6.98 – 6.93 (m, 2H), 5.29 (s, 2H), 3.30 – 3.27 (m, 2H), 2.87 – 2.83 (m, 2H), 2.38 (s, 3H), 2.26 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 165.6, 142.3, 140.6, 136.4, 136.2, 134.3, 129.2, 128.8, 128.6, 128.3, 127.3, 127.1, 126.4, 126.3, 116.7, 49.5, 28.2, 24.1, 21.5, 20.7. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_2\text{S}$ 405.1637; found 405.1643.

(E)-N-(1-benzyl-6-methoxy-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3c):




Prepared according to the general procedure **C** from 1-benzyl-6-methoxyquinolin-1-ium bromide (**1c**) (99 mg, 0.3 mmol). Flash column chromatography (28-30% EtOAc/Hex) afforded the desired product **3c** as a pale yellow solid (78 mg, 0.18 mmol,

62% yield). Reaction time: 19 h. Reaction temperature: 80 °C. Melting point: 142-143 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). ^1H NMR (400 MHz, CDCl_3): δ 7.63 (d, $J = 8.3$ Hz, 2H), 7.30 – 7.24 (m, 3H), 7.16 – 7.11 (m, 4H), 6.89 (d, $J = 8.9$ Hz, 1H), 6.72 (d, $J = 2.8$ Hz, 1H), 6.66 – 6.63 (m, 1H), 5.22 (s, 2H), 3.74 (s, 3H), 3.42 –

3.38 (m, 2H), 2.90 – 2.86 (m, 2H), 2.36 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.2, 156.4, 142.2, 140.6, 136.1, 132.2, 129.2, 128.9, 128.8, 127.3, 126.4, 126.3, 117.9, 113.7, 112.5, 55.6, 49.6, 27.9, 24.4, 21.5. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_3\text{S}$ 421.1586; found 421.1579.

(E)-N-(1-benzyl-6-chloro-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3d):




Prepared according to the general procedure **C** from *1-benzyl-6-chloroquinolin-1-ium bromide (1d)* (100 mg, 0.3 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3d** as a yellow solid (87.7 mg, 0.21 mmol, 69% yield).

Reaction time: 19 h. Reaction temperature: 80 °C. Melting point: 135-136 °C. R_f = 0.35

(EtOAc/Hex 3:7). ^1H NMR (500 MHz, CDCl_3): δ 7.62 (d, J = 8.2 Hz, 2H), 7.29 – 7.23 (m, 3H), 7.17 – 7.15 (m, 3H), 7.10 – 7.07 (m, 3H), 6.88 (d, J = 8.7, 1H), 5.22 (s, 2H), 3.44 – 3.41 (m, 2H), 2.92 – 2.88 (m, 2H), 2.36 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.3, 142.5, 140.1, 137.3, 135.5, 129.7, 129.2, 128.9, 127.8, 127.6, 127.4, 126.3, 126.2, 118.0, 49.5, 27.7, 23.9, 21.5. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_2\text{S}$ 425.1091; found 425.1082.

(E)-N-(1-benzyl-6-bromo-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3e):




Prepared according to the general procedure **C** from *1-benzyl-6-bromoquinolin-1-ium bromide (1e)* (113 mg, 0.3 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3e** as a white solid (89.9 mg, 0.19 mmol, 64% yield).

Reaction time: 19 h. Reaction temperature: 80 °C. Melting point: 140-141 °C. R_f = 0.35

(EtOAc/Hex 3:7). ^1H NMR (500 MHz, CDCl_3): δ 7.62 (d, J = 8.2 Hz, 2H), 7.32 – 7.23 (m, 5H), 7.16 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 6.7 Hz, 2H), 6.83 (d, J = 8.7, 1H), 5.21 (s, 2H), 3.44 – 3.42 (m, 2H), 2.92 – 2.89 (m, 2H), 2.36 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 165.4, 142.5, 140.2, 137.9, 135.6, 130.8, 130.7, 129.3, 129.2, 128.9, 127.5, 126.4, 126.3, 118.4, 117.4, 49.5, 27.8, 23.9, 21.6. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_2\text{SBr}$ 469.0585; found 469.0582.

(E)-N-(1-benzyl-6-phenyl-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3f):




Prepared according to the general procedure **C** from *1-benzyl-6-phenylquinolin-1-ium bromide (1f)* (112 mg, 0.3 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3f** as a yellow solid (95 mg, 0.203 mmol, 68% yield).

Reaction time: 19 h. Reaction temperature: 80 °C. Melting point: 131-132 °C. R_f = 0.3

(EtOAc/Hex 3:7). ^1H NMR (400 MHz, CDCl_3): δ 7.63 (d, J = 8.3 Hz, 2H), 7.52 – 7.49 (m, 2H), 7.43 – 7.39 (m, 3H), 7.37 – 7.27 (m, 5H), 7.17 – 7.14 (m, 4H), 7.04 (d, J = 8.5 Hz, 1H), 5.28 (s, 2H), 3.49 – 3.45 (m, 2H), 3.01 – 2.97 (m, 2H), 2.37 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.7, 142.4, 140.4, 139.9, 138.1, 137.5, 136.0, 129.2, 129.0, 128.9, 127.6, 127.5, 127.4, 126.9, 126.6, 126.4, 126.4, 117.2, 49.6, 28.1, 24.3, 21.6. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{27}\text{N}_2\text{O}_2\text{S}$ 467.1793; found 467.1792.

methyl (E)-1-benzyl-2-(tosylimino)-1,2,3,4-tetrahydroquinoline-6-carboxylate (3g):




Prepared according to the general procedure **C** from *1-benzyl-6-(methoxycarbonyl)quinolin-1-ium bromide (1g)* (107 mg, 0.3 mmol). Flash column chromatography (25-27% EtOAc/Hex) afforded the desired product **3g** as a white solid (57.5 mg, 0.13 mmol, 43% yield). Reaction time: 18 h. Reaction temperature:

80 °C. Melting point: 216-217 °C. R_f = 0.25 (EtOAc/Hex 3:7). ^1H NMR (400 MHz, CDCl_3): δ 7.86 (d, J = 1.8 Hz, 1H), 7.81 (dd, J = 8.6, 1.9 Hz, 1H), 7.62 (d, J = 8.3 Hz, 2H), 7.31 – 7.25 (m, 3H), 7.17 (d, J = 8.0 Hz, 2H), 7.12 – 7.09 (m, 2H), 7.01 (d, J = 8.6 Hz, 1H), 5.26 (s, 2H), 3.88 (s, 3H), 3.48 – 3.45 (m, 2H), 3.00 – 2.96 (m, 2H), 2.37 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 166.3, 165.8, 142.6, 142.5, 140.0, 135.5, 129.6, 129.2, 129.2, 128.9, 127.5, 126.9, 126.4, 126.3, 125.9, 116.6, 52.3, 49.5, 27.8, 23.9, 21.5. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ calcd


for C₂₅H₂₅N₂O₄S 449.1535; found 449.1534.

(E)-N-(1-benzyl-2-(tosylimino)-1,2,3,4-tetrahydroquinolin-6-yl)benzamide (3h):




Prepared according to the general procedure **C** from *6-benzamido-1-benzylquinolin-1-ium bromide (1h)* (126 mg, 0.3 mmol). Flash column chromatography (0-100% MeOH/DCM) afforded the desired product **3h** as a white solid (50.8 mg, 0.1 mmol, 33% yield). Reaction time: 30 h. Reaction temperature: 80 °C. Melting point: 257-258 °C. R_f = 0.3 (EtOAc/Hex 3:2). ¹H NMR (400 MHz, DMSO-d₆): δ 10.00 (s, 1H), 7.67 (d, J = 7.2 Hz, 2H), 7.48 (s, 1H), 7.36 – 7.25 (m, 6H), 7.08 – 6.98 (m, 5H), 6.93 (d, J = 7.3 Hz, 2H), 6.86 (d, J = 8.9 Hz, 1H), 5.06 (s, 2H), 3.08 – 3.04 (m, 2H+DMSO water), 2.64 – 2.61 (m, 2H), 2.10 (s, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-d₆): δ 165.5, 165.4, 142.1, 140.5, 136.0, 135.6, 134.7, 133.5, 131.6, 129.3, 128.6, 128.4, 127.6, 127.5, 127.0, 126.3, 125.7, 119.6, 119.1, 117.2, 47.8, 27.1, 23.3, 20.9. HRMS (ESI) m/z: [M+H]⁺ calcd for C₃₀H₂₈N₃O₃S 510.1851; found 510.1841.

(E)-N-(1-benzyl-7-methyl-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3i):




Prepared according to the general procedure **C** from *1-benzyl-7-methylquinolin-1-ium bromide (1i)* (94 mg, 0.3 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3i** as a white solid (79.8 mg, 0.198 mmol, 66% yield). Reaction time: 19 h. Reaction temperature: 80 °C. Melting point: 130-131 °C. R_f = 0.3 (EtOAc/Hex 1:4). ¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, J = 8.3 Hz, 2H), 7.29 – 7.24 (m, 3H), 7.14 – 7.12 (m, 4H), 7.06 (d, J = 7.5 Hz, 1H), 6.86 (d, J = 7.1 Hz, 1H), 6.79 (s, 1H), 5.22 (s, 2H), 3.41 – 3.37 (m, 2H), 2.89 – 2.85 (m, 2H), 2.36 (s, 3H), 2.22 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 165.7, 142.1, 140.4, 138.7, 137.6, 136.1, 129.0, 128.7, 127.6, 127.2, 126.3, 126.2, 125.1, 124.1, 117.4, 49.5, 28.2, 23.6, 21.5, 21.4. HRMS (ESI) m/z: [M+H]⁺ calcd for C₂₄H₂₅N₂O₂S 405.1637; found 405.1639.

(E)-N-(1-benzyl-5-bromo-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3j):




Prepared according to the general procedure **C** from *1-benzyl-5-bromoquinolin-1-ium bromide (1j)* (113 mg, 0.3 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3j** as a white solid (80.7 mg, 0.17 mmol, 57% yield). Reaction time: 21 h. Reaction temperature: 80 °C. Melting point: 207-208 °C. R_f = 0.35 (EtOAc/Hex 3:7). ¹H NMR (400 MHz, CDCl₃): δ 7.62 (d, J = 8.3 Hz, 2H), 7.31 – 7.25 (m, 4H), 7.16 (d, J = 7.9 Hz, 2H), 7.11 – 7.09 (m, 2H), 7.02 – 6.98 (m, 1H), 6.94 – 6.92 (m, 1H), 5.23 (s, 2H), 3.45 – 3.41 (m, 2H), 3.07 – 3.04 (m, 2H), 2.37 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 165.5, 142.5, 140.3, 140.2, 135.7, 129.3, 128.9, 128.6, 128.5, 127.5, 127.3, 126.4, 126.3, 123.5, 116.2, 49.9, 27.4, 24.0, 21.6. HRMS (ESI) m/z: [M+H]⁺ calcd for C₂₃H₂₂N₂O₂SBr 469.0585; found 469.0582.

(E)-N-(1-benzyl-5-phenyl-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3k):




Prepared according to the general procedure **C** from *1-benzyl-5-phenylquinolin-1-ium bromide (1k)* (113 mg, 0.3 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3k** as a yellow solid (86.6 mg, 0.186 mmol, 62% yield). Reaction time: 24 h. Reaction temperature: 80 °C. Melting point: 177-178 °C. R_f = 0.3 (EtOAc/Hex 1:4). ¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J = 8.3 Hz, 2H), 7.46 – 7.36 (m, 3H), 7.33 – 7.27 (m, 5H), 7.21 – 7.13 (m, 5H), 7.08 – 7.06 (m, 1H), 7.01 (d, J = 8.1 Hz, 1H), 5.30 (s, 2H), 3.30 – 3.27 (m, 2H), 2.88 – 2.85 (m, 2H), 2.36 (s, 3H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 166.0, 142.3, 141.2, 140.5, 139.8, 139.5, 136.1, 129.2, 129.1, 128.9, 128.5, 127.7, 127.3, 127.3, 126.4, 126.3, 125.3, 116.2, 50.2, 27.9, 21.8, 21.5. HRMS (ESI) m/z: [M+H]⁺ calcd for C₂₉H₂₇N₂O₂S 467.1793; found 467.1781.

(E)-N-(1-benzylquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3a'')


Prepared according to the general procedure **C** from *1-benzyl-3-bromoquinolin-1-ium bromide (1l)* (113 mg, 0.3 mmol). Flash column chromatography (30-35% EtOAc/Hex) afforded the desired product **3a''** as a yellow solid (31 mg, 0.08 mmol, 26% yield).

Reaction time: 19 h. Reaction temperature: 80 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.03 (d, $J = 9.6$ Hz, 1H), 7.86 (d, $J = 9.6$ Hz, 1H), 7.76 (d, $J = 8.3$ Hz, 2H), 7.65 (dd, $J = 7.8, 1.3$ Hz, 1H), 7.55-7.51 (m, 1H), 7.46 (d, $J = 8.6$ Hz, 1H), 7.32 – 7.29 (m, 1H), 7.26 – 7.24 (m, 3H), 7.17 (d, $J = 8.3$ Hz, 2H), 7.12 – 7.11 (m, 2H), 5.76 (s, 2H), 2.36 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 156.2, 142.1, 140.9, 139.8, 138.9, 135.3, 132.2, 129.4, 129.2, 128.9, 127.7, 126.7, 126.5, 124.1, 122.2, 117.4, 116.4, 49.1, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{21}\text{N}_2\text{O}_2\text{S}$ 389.1324; found 389.1324.

(E)-N-(1-benzyl-3-methyl-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3m):


Prepared according to the general procedure **C** from *1-benzyl-3-methylquinolin-1-ium bromide (1m)* (94 mg, 0.3 mmol). Flash column chromatography (16-18% EtOAc/Hex) afforded the desired product **3m** as a viscous oil (22 mg, 0.054 mmol, 18% yield). Reaction

time: 21 h. Reaction temperature: 80 °C. $R_f = 0.3$ (EtOAc/Hex 1:4). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.63 (d, $J = 8.3$ Hz, 2H), 7.31 – 7.24 (m, 3H), 7.19 – 7.15 (m, 3H), 7.13 – 7.10 (m, 3H), 7.08 – 7.04 (m, 1H), 6.97 (d, $J = 8.1$ Hz, 1H), 5.58 (d, $J = 16.2$ Hz, 1H), 4.83 (d, $J = 16.1$ Hz, 1H), 4.34 – 4.27 (m, 1H), 3.24 (dd, $J = 15.8, 4.9$ Hz, 1H), 2.64 (dd, $J = 15.9, 1.9$ Hz, 1H), 2.36 (s, 3H), 1.21 (d, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.8, 142.2, 140.7, 138.3, 136.3, 129.2, 129.1, 128.9, 127.8, 127.3, 126.3, 126.2, 125.1, 124.7, 116.5, 49.6, 31.8, 31.3, 21.5, 15.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_2\text{S}$ 405.1637; found 405.1626.

1-benzyl-3-methyl-1,2,3,4-tetrahydroquinoline (3m')


Flash column chromatography (4-5% EtOAc/Hex) afforded the desired product **3m'** as a viscous oil (27 mg, 0.11 mmol, 38% yield). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.31 – 7.20 (m, 5H),

6.98 – 6.92 (m, 2H), 6.58 – 6.53 (m, 1H), 6.51 – 6.47 (m, 1H), 4.45 (s, 2H), 3.28 – 3.23 (m, 1H), 3.03 – 2.97 (m, 1H), 2.83 – 2.76 (m, 1H), 2.52 – 2.46 (m, 1H), 2.19 – 2.09 (m, 1H), 1.04 – 1.01 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 145.3, 139.1, 129.2, 128.7, 127.3, 126.9, 126.7, 121.9, 116.0, 110.8, 56.9, 55.3, 36.6, 27.4, 19.2. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{20}\text{N}$ 238.1596; found 238.1594.

(E)-4-methyl-N-(1-methyl-3,4-dihydroquinolin-2(1H)-ylidene)benzenesulfonamide (3p):

Prepared according to the general procedure **C** from *1-methylquinolin-1-ium iodide (1p)* (81 mg, 0.3 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3p** as a yellow solid (34 mg, 0.108 mmol, 36% yield). Reaction time: 15 h.

Melting point: 168-170 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.87 (d, $J = 8.3$ Hz, 2H), 7.29 – 7.25 (m, 3H), 7.17 (d, $J = 6.4$ Hz, 1H), 7.10 – 7.08 (m, 1H), 7.05 (d, $J = 8.5$ Hz, 1H), 3.44 (s, 3H), 3.33 – 3.30 (m, 2H), 2.86 – 2.82 (m, 2H), 2.41 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 166.1, 142.5, 140.7, 139.4, 129.4, 127.8, 127.8, 127.2, 126.5, 124.5, 116.2, 33.4, 28.1, 23.9, 21.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{19}\text{N}_2\text{O}_2\text{S}$ 315.1167; found 315.1158.


(E)-4-methyl-N-(1-pentyl-3,4-dihydroquinolin-2(1H)-ylidene)benzenesulfonamide (3q):

Prepared according to the general procedure **C** from *1-pentylquinolin-1-ium bromide (1q)* (84 mg, 0.3 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3q** as a white solid (72 mg, 0.194 mmol, 65% yield). Reaction time: 15 h.

Melting point: 137-138 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.85 (d, $J = 8.3$ Hz, 2H), 7.28 – 7.24 (m, 3H), 7.16 (d, $J = 6.3$ Hz, 1H), 7.08 – 7.05 (m, 2H), 3.97 – 3.94 (m, 2H), 3.32 – 3.29 (m, 2H), 2.84 – 2.81 (m, 2H), 2.41 (s, 3H), 1.69 – 1.64 (m, 2H), 1.28 – 1.25 (m, 4H), 0.83 (t, $J = 6.9$ Hz,


3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 165.0, 142.3, 140.9, 138.5, 129.3, 128.1, 127.8, 127.4, 126.4, 124.3, 116.2, 45.9, 29.1, 28.1, 26.4, 24.1, 22.3, 21.6, 14.0. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{27}\text{N}_2\text{O}_2\text{S}$ (ESI $^+$, $[\text{M}+\text{H}]^+$): 371.1793; found 371.1798.

(E)-N-(1-allyl-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3r):




Prepared according to the general procedure **C** from 1-allylquinolin-1-ium bromide (**1r**) (75 mg, 0.3 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3r** as a white solid (59.4 mg, 0.178 mmol, 59% yield). Reaction time: 15 h. Melting point: 92-94 °C. R_f = 0.3 (EtOAc/Hex 1:4). ^1H NMR (500 MHz, CDCl_3): δ 7.83 (d, J = 8.2 Hz, 2H), 7.26 (d, J = 8.2 Hz, 2H), 7.22 (t, J = 7.8 Hz, 1H), 7.16 (d, J = 7.3 Hz, 1H), 7.09 – 7.05 (m, 2H), 5.91 – 5.83 (m, 1H), 5.20 (d, J = 10.4 Hz, 1H), 5.11 (d, J = 17.3 Hz, 1H), 4.62 (d, J = 4.9 Hz, 2H), 3.35 – 3.32 (m, 2H), 2.87 – 2.84 (m, 2H), 2.40 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 165.3, 142.4, 140.7, 138.8, 131.6, 129.3, 127.9, 127.8, 127.2, 126.5, 124.4, 117.4, 116.6, 48.7, 28.0, 24.1, 21.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2\text{S}$ 341.1324; found 341.1319.

(E)-4-methyl-N-(1-phenethyl-3,4-dihydroquinolin-2(1H)-ylidene)benzenesulfonamide (3s):




Prepared according to the general procedure **C** from 1-phenethylquinolin-1-ium bromide (**1s**) (95 mg, 0.3 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3s** as a yellow solid (89.6 mg, 0.22 mmol, 74% yield). Reaction time: 28 h. Reaction temperature: 95 °C. Melting point: 170-171 °C. R_f = 0.4 (EtOAc/Hex 3:7). ^1H NMR (400 MHz, CDCl_3): δ 7.89 (d, J = 8.3 Hz, 2H), 7.32 – 7.26 (m, 3H), 7.22 – 7.17 (m, 4H), 7.14 – 7.07 (m, 2H), 7.03 – 7.01 (m, 2H), 4.18 – 4.14 (m, 2H), 3.35 – 3.32 (m, 2H), 2.97 – 2.93 (m, 2H), 2.83 – 2.79 (m, 2H), 2.44 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 164.9, 142.5, 140.8, 138.4, 138.1, 129.3, 128.8, 128.6, 128.1, 127.9, 127.4, 126.7, 126.5, 124.4, 116.0, 47.5, 33.0, 28.2, 24.0, 21.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_2\text{S}$ 405.1637; found 405.1638.

(E)-4-methyl-N-(1-(4-nitrobenzyl)-3,4-dihydroquinolin-2(1H)-ylidene)benzenesulfonamide (3t):




Prepared according to the general procedure **C** from 1-(4-nitrobenzyl)quinolin-1-ium bromide (**1t**) (103 mg, 0.3 mmol). Flash column chromatography (40-45% EtOAc/Hex) afforded the desired product **3t** as a yellow solid (60 mg, 0.137 mmol, 46% yield). Reaction time: 15 h. Melting point: 225-226 °C. R_f = 0.3 (EtOAc/Hex 2:3). ^1H NMR (500 MHz, CDCl_3): δ 8.09 (d, J = 8.8 Hz, 2H), 7.58 (d, J = 8.3 Hz, 2H), 7.25 – 7.22 (m, 3H), 7.18 – 7.14 (m, 3H), 7.10 – 7.07 (m, 1H), 6.85 (d, J = 8.1 Hz, 1H), 5.29 (s, 2H), 3.46 – 3.43 (m, 2H), 2.96 – 2.93 (m, 2H), 2.37 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 165.7, 147.3, 143.9, 142.8, 140.1, 138.5, 129.3, 128.3, 128.1, 127.2, 127.2, 126.3, 124.9, 124.1, 116.2, 49.3, 27.9, 24.0, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{22}\text{N}_3\text{O}_4\text{S}$ (ESI $^+$, $[\text{M}+\text{H}]^+$): 436.1331; found 436.1320.

(E)-N-(1-(4-cyanobenzyl)-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3u):




Prepared according to the general procedure **C** from 1-(4-cyanobenzyl)quinolin-1-ium bromide (**1u**) (97 mg, 0.3 mmol). Flash column chromatography (35-40% EtOAc/Hex) afforded the desired product **3u** as a yellow solid (91 mg, 0.21 mmol, 73% yield). Reaction time: 28 h. Reaction temperature: 95 °C. Melting point: 210-212 °C. R_f = 0.3 (EtOAc/Hex 2:3). ^1H NMR (500 MHz, CDCl_3): δ 7.57 (d, J = 8.3 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 7.22 – 7.15 (m, 6H), 7.09 – 7.06 (m, 1H), 6.84 (d, J = 8.1 Hz, 1H), 5.25 (s, 2H), 3.45 – 3.42 (m, 2H), 2.95 – 2.92 (m, 2H), 2.39 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 165.7, 142.7, 141.8, 140.1, 138.5, 132.6, 129.2, 128.2, 128.1, 127.2, 127.1, 126.3, 124.9, 118.6, 116.3, 111.3, 49.5, 27.9, 24.0, 21.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{22}\text{N}_3\text{O}_2\text{S}$ 416.1433; found 416.1423.

(E)-N-(1-(3-bromobenzyl)-3,4-dihydroquinolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3v):


Prepared according to the general procedure **C** from *1-(3-bromobenzyl)quinolin-1-ium bromide (1v)* (113 mg, 0.3 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3v** as a white solid (96.5 mg, 0.205 mmol, 68% yield).

Reaction time: 15 h. Melting point: 177-178 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.62 (d, $J = 8.3$ Hz, 2H), 7.38 (dd, $J = 7.9, 0.7$ Hz, 1H), 7.24 (s, 1H), 7.19 (d, $J = 7.8$ Hz, 3H), 7.17 – 7.12 (m, 2H), 7.08 – 7.03 (m, 2H), 6.92 (d, $J = 8.0$ Hz, 1H), 5.19 (s, 2H), 3.43 – 3.39 (m, 2H), 2.94 – 2.91 (m, 2H), 2.38 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.8, 142.5, 140.2, 138.8, 138.6, 130.6, 130.5, 129.5, 129.3, 128.1, 128.0, 127.2, 126.4, 124.9, 124.7, 122.9, 116.6, 49.2, 27.9, 24.0, 21.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_2\text{S}^{79}\text{Br}$ 469.0585; found 469.0598.

(E)-4-methyl-N-(1-(3-(trifluoromethyl)benzyl)-3,4-dihydroquinolin-2(1H)-ylidene)benzenesulfonamide (3w):


Prepared according to the general procedure **C** from *1-(3-(trifluoromethyl)benzyl)quinolin-1-ium bromide (1w)* (110 mg, 0.3 mmol). Flash column chromatography (22-25% EtOAc/Hex) afforded the desired product **3w** as a white solid (116.3 mg, 0.255 mmol, 84% yield). Reaction time: 30 h. Melting point: 144-146 °C. $R_f = 0.3$ (EtOAc/Hex 3:7).

$^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.59 (d, $J = 8.3$ Hz, 2H), 7.51 (d, $J = 7.8$ Hz, 1H), 7.42 – 7.38 (m, 2H), 7.28 (d, $J = 7.9$ Hz, 1H), 7.21 (d, $J = 7.5$ Hz, 1H), 7.16 – 7.14 (m, 3H), 7.09 – 7.05 (m, 1H), 6.91 (d, $J = 8.1$ Hz, 1H), 5.27 (s, 2H), 3.45 – 3.41 (m, 2H), 2.96 – 2.92 (m, 2H), 2.36 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.8, 142.6, 140.1, 138.7, 137.4, 131.2 (q, $J = 32.3$ Hz), 129.6, 129.4, 129.2, 128.1, 128.0, 127.2, 126.2, 124.0 (q, $J = 272.5$ Hz), 124.7, 124.2 (q, $J = 3.7$ Hz), 123.2 (q, $J = 3.7$ Hz), 116.4, 49.4, 27.9, 23.9, 21.5. $^{19}\text{F NMR}$ (376 MHz, CDCl_3): δ -62.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{22}\text{F}_3\text{N}_2\text{O}_2\text{S}$ 459.1354; found 459.1351.

(E)-N-(1-benzyl-3,4-dihydro-1,10-phenanthrolin-2(1H)-ylidene)-4-methylbenzenesulfonamide (3x):

Prepared according to the general procedure **C** from *1-benzyl-1,10-phenanthrolin-1-ium bromide (1x)* (105 mg, 0.3 mmol). Flash column chromatography (40% EtOAc/Hex) afforded the desired product **3x** as a colorless oil (80.5 mg, 0.182 mmol, 61% yield).

Reaction time: 16 h. Reaction temperature: 80 °C. $R_f = 0.25$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.88 (dd, $J = 4.1, 1.6$ Hz, 1H), 8.13 (dd, $J = 8.3, 1.5$ Hz, 1H), 7.73 (d, $J = 8.2$ Hz, 2H), 7.59 (d, $J = 8.2$ Hz, 1H), 7.40 (dd, $J = 8.3, 4.1$ Hz, 1H), 7.37 (d, $J = 8.2$ Hz, 1H), 7.24 (d, $J = 8.1$ Hz, 2H), 7.08 – 7.05 (m, 3H), 6.97 – 6.95 (m, 2H), 6.11 (s, 2H), 3.36 (brs, 2H), 2.93 – 2.90 (m, 2H), 2.42 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 167.8, 148.8, 142.2, 140.5, 138.3, 136.8, 134.9, 132.6, 129.7, 129.2, 128.7, 128.1, 127.6, 126.9, 126.5, 126.1, 125.5, 120.9, 52.2, 28.8, 25.4, 21.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{24}\text{N}_3\text{O}_2\text{S}$ 442.1589; found 442.1585.


5-methyl-2-(prop-1-en-2-yl)cyclohexyl**(E)-1-benzyl-2-(tosylimino)-1,2,3,4-tetrahydroquinoline-6-carboxylate (3y):**

Prepared according to the general procedure **C** from *1-benzyl-6-(((5-methyl-2-(prop-1-en-2-yl)cyclohexyl)oxy)carbonyl)quinolin-1-ium bromide (1y)* (96 mg, 0.2 mmol). Flash column chromatography (18-20% EtOAc/Hex) afforded the desired product **3y** as a sticky solid (46.7mg, 0.08 mmol, 41% yield). Reaction time: 66 h.

Reaction temperature: 95 °C. $R_f = 0.3$ (EtOAc/Hex 1:4). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.81 (d, $J = 1.7$ Hz, 1H), 7.77 (dd, $J = 8.5, 1.9$ Hz, 1H), 7.62 (d, $J = 8.3$ Hz, 2H), 7.30 – 7.25 (m, 3H), 7.16 (d, $J = 8.0$ Hz, 2H), 7.11 – 7.09 (m, 2H), 6.99 (d, $J = 8.6$ Hz, 1H), 5.30-5.20 (m, 2H), 4.99 (td, $J = 10.8, 4.4$ Hz, 1H), 4.75 (s, 1H), 4.69 – 4.68 (m, 1H), 3.50 – 3.41 (m, 2H), 2.97 (t, $J = 7.3$ Hz, 2H), 2.37 (s, 3H), 2.29 – 2.22 (m, 1H), 2.12 – 2.09 (m, 1H),


1.78 – 1.70 (m, 2H), 1.66 (s, 3H+1H (water)), 1.63 – 1.59 (m, 1H), 1.49 – 1.37 (m, 1H), 1.15 – 1.06 (m, 1H), 1.05 – 0.97 (m, 1H), 0.94 (d, $J = 6.5$ Hz, 3H), 0.89 – 0.86 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.9, 165.2, 146.2, 142.6, 142.4, 140.1, 135.6, 129.6, 129.3, 129.2, 128.9, 127.5, 126.9, 126.7, 126.4, 126.3, 116.5, 112.1, 74.5, 51.0, 49.5, 40.6, 34.3, 31.5, 30.6, 27.9, 23.9, 22.1, 21.6, 19.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{34}\text{H}_{39}\text{N}_2\text{O}_4\text{S}$ 571.2631; found 571.2627.

(3R,9S,13S,17S)-17-acetyl-9,13-dimethyl-2,3,4,8,9,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[*c*]phenanthren-3-yl (E)-1-benzyl-2-(tosylimino)-1,2,3,4-tetrahydroquinoline-6-carboxylate (3z):




Prepared according to the general procedure **C** from 6-(((3*R*,3*aS*,9*R*,11*aS*)-3-acetyl-3*a*,11*a*-dimethyl-2,3,3*a*,4,5,5*a*,6,8,9,10,11,11*a*,11*b*,11*c*-tetradecahydro-1*H*-cyclopenta[*c*]phenanthren-9-yl)oxy)carbonyl)-1-benzylquinolin-1-ium bromide (**1z**) (96 mg, 0.15 mmol). Flash column chromatography (22-25% EtOAc/Hex) afforded the desired product **3z** as a white solid (73.5 mg, 0.10 mmol, 67% yield). Reaction time: 30 h. Reaction temperature: 95 °C. Melting point: 210-212 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). ^1H NMR (400 MHz, CDCl_3): δ 7.86 – 7.81 (m, 2H), 7.63 (d, $J = 8.3$ Hz, 2H), 7.28 – 7.25 (m, 3H), 7.17 (d, $J = 8.0$ Hz, 2H), 7.11 – 7.09 (m, 2H), 7.01 (d, $J = 8.6$ Hz, 1H), 5.41 (d, $J = 3.8$ Hz, 1H), 5.26 (s, 2H), 4.86 – 4.78 (m, 1H), 3.49 – 3.45 (m, 2H), 3.01 – 2.98 (m, 2H), 2.54 (t, $J = 8.9$ Hz, 1H), 2.43 (d, $J = 7.7$ Hz, 2H), 2.37 (s, 3H), 2.22 – 2.17 (m, 1H), 2.13 (s, 3H), 2.07 – 1.89 (m, 4H), 1.75 – 1.65 (m, 3H), 1.56 – 1.42 (m, 4H), 1.28 – 1.16 (m, 4H), 1.05 (s, 4H), 0.64 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 209.6, 165.8, 165.2, 142.6, 142.4, 140.1, 139.7, 135.6, 129.6, 129.3, 129.2, 128.9, 127.5, 126.9, 126.6, 126.4, 126.3, 122.7, 116.6, 74.7, 63.8, 56.9, 50.0, 49.5, 44.1, 38.9, 38.3, 37.1, 36.8, 31.9, 31.9, 31.6, 27.9, 27.9, 24.6, 23.9, 22.9, 21.6, 21.2, 19.5, 13.3. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{45}\text{H}_{53}\text{N}_2\text{O}_5\text{S}$ 733.3675; found 733.3678.

(E)-N-(2-benzyl-1,4-dihydroisoquinolin-3(2H)-ylidene)-4-methylbenzenesulfonamide (5a):




Prepared according to the general procedure **C** from 2-benzylisoquinolin-2-ium bromide (**4a**) (90 mg, 0.3 mmol). Flash column chromatography (28-30% EtOAc/Hex) afforded the desired product **5a** as a yellow solid (110 mg, 0.28 mmol, 94% yield). Reaction time: 16 h. Reaction temperature: 80 °C. Melting point: 164-165 °C. $R_f = 0.2$ (EtOAc/Hex 1:4). ^1H NMR (400 MHz, CDCl_3): δ 7.82 (d, $J = 8.3$ Hz, 2H), 7.29 – 7.27 (m, 3H), 7.26 – 7.24 (m, 3H), 7.23 – 7.19 (m, 4H), 7.04 (d, $J = 7.5$ Hz, 1H), 4.85 (s, 2H), 4.41 (s, 4H), 2.38 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 164.7, 142.1, 141.1, 135.3, 130.2, 129.9, 129.3, 128.9, 128.3, 128.2, 128.1, 127.6, 127.2, 126.4, 125.0, 53.1, 50.9, 33.8, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O}_2\text{S}$ 391.1480; found 391.1474. The analytical data of the compound was in complete agreement with the literature.⁷


(E)-N-(2-benzyl-6-methyl-1,4-dihydroisoquinolin-3(2H)-ylidene)-4-methylbenzenesulfonamide (5b):




Prepared according to the general procedure **C** from 2-benzyl-6-methylisoquinolin-2-ium bromide (**4b**) (94 mg, 0.3 mmol). Flash column chromatography (28-30% EtOAc/Hex) afforded the desired product **5b** as a white solid (90.4 mg, 0.22 mmol, 74% yield). Reaction time: 16 h. Reaction temperature: 80 °C. Melting point: 167 °C. $R_f = 0.2$ (EtOAc/Hex 1:4). ^1H NMR (500 MHz, CDCl_3): δ 7.83 (d, $J = 8.2$ Hz, 2H), 7.29 – 7.23 (m, 5H), 7.20 – 7.19 (m, 2H), 7.06 (s, 1H), 7.02 (d, $J = 7.7$ Hz, 1H), 6.92 (d, $J = 7.7$ Hz, 1H), 4.86 (s, 2H), 4.38 (s, 2H), 2.39 (s, 3H), 2.32 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 164.9, 142.3, 140.9, 138.2, 135.1, 129.7, 129.3, 128.9, 128.2, 128.1, 128.1, 128.0, 127.1, 126.5, 124.9, 53.3, 50.8, 33.8, 21.6, 21.2. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_2\text{S}$ 405.1637; found 405.1632.

(E)-N-(2-benzyl-6-bromo-1,4-dihydroisoquinolin-3(2H)-ylidene)-4-methylbenzenesulfonamide (5c):


Prepared according to the general procedure **C** from *2-benzyl-6-bromoisoquinolin-2-ium bromide (4c)* (113 mg, 0.3 mmol). Flash column chromatography (28-30% EtOAc/Hex) afforded the desired product **5c** as a pale yellow solid (85.6 mg, 0.18 mmol, 61% yield). Reaction time: 15 h. Reaction temperature: 80 °C. Melting point: 183-184 °C. $R_f = 0.3$ (EtOAc/Hex 2:3). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.81 (d, $J = 8.3$ Hz, 2H), 7.38 (d, $J = 1.5$ Hz, 1H), 7.34 – 7.31 (m, 1H), 7.29 – 7.26 (m, 3H), 7.24 (d, $J = 7.9$ Hz, 2H), 7.19 – 7.17 (m, 2H), 6.91 (d, $J = 8.1$ Hz, 1H), 4.83 (s, 2H), 4.38 (s, 2H), 4.35 (s, 2H), 2.39 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 163.9, 142.3, 140.9, 135.0, 132.2, 130.5, 130.4, 129.3, 129.2, 128.9, 128.2, 126.7, 126.4, 122.0, 53.1, 50.3, 33.4, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_2\text{SBr}$ 469.0585; found 469.0582.

(E)-N-(2-benzyl-5-bromo-1,4-dihydroisoquinolin-3(2H)-ylidene)-4-methylbenzenesulfonamide (5d):


Prepared according to the general procedure **C** from *2-benzyl-5-bromoisoquinolin-2-ium bromide (4d)* (113 mg, 0.3 mmol). Flash column chromatography (28-30% EtOAc/Hex) afforded the desired product **5d** as a pale yellow solid (95.6 mg, 0.203 mmol, 68% yield). Reaction time: 17 h. Reaction temperature: 80 °C. Melting point: 163-165 °C. $R_f = 0.35$ (EtOAc/Hex 2:3). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.85 (d, $J = 8.3$ Hz, 2H), 7.46 (d, $J = 7.6$ Hz, 1H), 7.29 – 7.26 (m, 3H), 7.26 – 7.22 (m, 4H), 7.05 (t, $J = 7.8$ Hz, 1H), 6.97 (d, $J = 7.5$ Hz, 1H), 4.88 (s, 2H), 4.43 (s, 2H), 4.39 (s, 2H), 2.38 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 163.7, 142.3, 140.7, 135.0, 131.9, 131.8, 129.5, 129.3, 128.9, 128.5, 128.3, 128.1, 126.6, 124.2, 123.3, 52.9, 50.6, 33.7, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_2\text{S}^{81}\text{Br}$ 471.0565; found 471.0565.

(E)-N-(2-benzyl-5-nitro-1,4-dihydroisoquinolin-3(2H)-ylidene)-4-methylbenzenesulfonamide (5e):


Prepared according to the general procedure **C** from *2-benzyl-5-bromoisoquinolin-2-ium bromide (4e)* (103 mg, 0.3 mmol). Flash column chromatography (50-52% EtOAc/Hex) afforded the desired product **5e** as a yellow solid (101.5 mg, 0.233 mmol, 78% yield). Reaction time: 19 h. Reaction temperature: 80 °C. Melting point: 192 °C. $R_f = 0.3$ (EtOAc/Hex 1:1). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.98 (d, $J = 8.1$ Hz, 1H), 7.88 (d, $J = 8.0$ Hz, 2H), 7.42 – 7.39 (m, 1H), 7.34 – 7.32 (m, 4H), 7.29 – 7.26 (m, 4H), 4.94 (s, 2H), 4.71 (s, 2H), 4.50 (s, 2H), 2.41 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 162.8, 147.8, 142.5, 140.4, 134.8, 132.9, 130.3, 129.4, 129.1, 128.4, 128.0, 126.9, 125.5, 124.7, 53.0, 49.9, 30.2, 21.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{22}\text{N}_3\text{O}_4\text{S}$ 436.1331; found 436.1328.

N-((E)-2-benzyl-5-((E)-styryl)-1,4-dihydroisoquinolin-3(2H)-ylidene)-4-methylbenzenesulfonamide (5f):


Prepared according to the general procedure **C** from *(E)-2-benzyl-5-styrylisoquinolin-2-ium bromide (4f)* (120 mg, 0.3 mmol). Flash column chromatography (1-99% acetone/DCM) afforded the desired product **5f** as a white solid (109.3 mg, 0.222 mmol, 74% yield). Reaction time: 19 h. Reaction temperature: 80 °C. Melting point: 148-150 °C. $R_f = 0.25$ (EtOAc/Hex 2:3). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.84 (d, $J = 8.2$ Hz, 1H), 7.60 (d, $J = 7.4$ Hz, 2H), 7.57 (d, $J = 7.8$ Hz, 2H), 7.44 (t, $J = 7.6$ Hz, 2H), 7.36 – 7.31 (m, 4H), 7.29 – 7.23 (m, 4H), 7.14 (d, $J = 8.1$ Hz, 2H), 7.03 – 6.96 (m, 2H), 4.94 (s, 2H), 4.47 (s, 2H), 4.45 (s, 2H), 2.33 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 164.7, 142.2, 140.9, 137.1, 136.0, 135.2, 132.7, 130.7, 129.3, 128.9, 128.9, 128.3, 128.2, 128.1, 127.5, 127.4, 126.9, 126.5, 125.5, 124.2, 124.1, 53.0, 50.9, 30.9, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{31}\text{H}_{29}\text{N}_2\text{O}_2\text{S}$ 493.1950; found 493.1946.

(E)-4-methyl-N-(2-(2-nitrobenzyl)-1,4-dihydroisoquinolin-3(2H)-ylidene)benzenesulfonamide (5g):


Prepared according to the general procedure **C** from 2-(2-nitrobenzyl)isoquinolin-2-ium bromide (**4g**) (103 mg, 0.3 mmol). Flash column chromatography (80-20% DCM/Hex) afforded the desired product **5g** as a yellow solid (110.7 mg, 0.254 mmol, 85% yield). Reaction time: 30 h. Melting point: 217-218 °C. $R_f = 0.25$ (EtOAc/Hex 2:3). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.04 (d, $J = 7.5$ Hz, 1H), 7.67 (d, $J = 8.0$ Hz, 2H), 7.49 – 7.46 (m, 1H), 7.43 – 7.40 (m, 1H), 7.35 – 7.29 (m, 2H), 7.28 – 7.26 (m, 1H), 7.19 (d, $J = 7.9$ Hz, 2H), 7.14 (d, $J = 7.6$ Hz, 1H), 7.09 (d, $J = 7.4$ Hz, 1H), 5.20 (s, 2H), 4.52 (s, 2H), 4.47 (s, 2H), 2.37 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.4, 148.5, 142.3, 140.6, 134.0, 131.0, 130.1, 129.9, 129.3, 128.6, 128.5, 127.8, 127.5, 126.3, 125.4, 125.1, 52.1, 50.8, 33.9, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{22}\text{N}_3\text{O}_4\text{S}$ 436.1331; found 436.1330.

(E)-N-(2-(3-bromobenzyl)-1,4-dihydroisoquinolin-3(2H)-ylidene)-4-methylbenzenesulfonamide (5h):


Prepared according to the general procedure **C** from 2-(3-bromobenzyl)isoquinolin-2-ium bromide (**4h**) (113 mg, 0.3 mmol). Flash column chromatography (28-30% EtOAc/Hex) afforded the desired product **5h** as a white solid (135.1 mg, 0.287 mmol, 96% yield). Reaction time: 30 h. Melting point: 153 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.81 (d, $J = 8.3$ Hz, 2H), 7.41 – 7.38 (m, 1H), 7.36 – 7.35 (m, 1H), 7.30 – 7.20 (m, 5H), 7.15 – 7.12 (m, 2H), 7.07 (d, $J = 7.4$ Hz, 1H), 4.79 (s, 2H), 4.43 (s, 2H), 4.40 (s, 2H), 2.39 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 164.8, 142.3, 140.9, 137.7, 131.3, 131.2, 130.5, 129.9, 129.8, 129.4, 128.4, 127.7, 127.3, 126.7, 126.4, 125.0, 122.9, 52.7, 51.2, 33.7, 21.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{22}\text{N}_2\text{O}_2\text{S}^{79}\text{Br}$ 469.0585; found 469.0587.

(E)-4-methyl-N-(2-(4-nitrobenzyl)-1,4-dihydroisoquinolin-3(2H)-ylidene)benzenesulfonamide (5i):


Prepared according to the general procedure **C** from 2-(4-nitrobenzyl)isoquinolin-2-ium bromide (**4i**) (103 mg, 0.3 mmol). Flash column chromatography (2-98% acetone/DCM) afforded the desired product **5i** as a yellow solid (104 mg, 0.239 mmol, 79% yield). Reaction time: 30 h. Melting point: 210-212 °C. $R_f = 0.2$ (EtOAc/Hex 3:2). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.09 (d, $J = 8.7$ Hz, 2H), 7.74 (d, $J = 8.3$ Hz, 2H), 7.33 – 7.29 (m, 3H), 7.28 – 7.25 (m, 2H), 7.22 (d, $J = 7.9$ Hz, 2H), 7.08 (d, $J = 7.3$ Hz, 1H), 4.91 (s, 2H), 4.49 (s, 2H), 4.44 (s, 2H), 2.39 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 164.9, 147.6, 142.9, 142.5, 140.7, 129.9, 129.8, 129.3, 128.6, 128.5, 127.7, 127.4, 126.3, 125.0, 124.0, 52.8, 51.7, 33.7, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{22}\text{N}_3\text{O}_4\text{S}$ 436.1331; found 436.1322.

(E)-4-methyl-N-(2-(naphthalen-2-ylmethyl)-1,4-dihydroisoquinolin-3(2H)-ylidene)benzenesulfonamide (5j):


Prepared according to the general procedure **C** from 2-(naphthalen-1-ylmethyl)isoquinolin-2-ium bromide (**4j**) (105 mg, 0.3 mmol). Flash column chromatography (28-30% EtOAc/Hex) afforded the desired product **5j** as a yellow solid (129.5 mg, 0.29 mmol, 98% yield). Reaction time: 30 h. Melting point: 167-168 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.84 (d, $J = 8.1$ Hz, 2H), 7.81 – 7.79 (m, 1H), 7.75 (d, $J = 8.4$ Hz, 1H), 7.72 – 7.70 (m, 1H), 7.62 (d, 1H), 7.48 – 7.45 (m, 2H), 7.33 – 7.31 (m, 1H), 7.28 – 7.24 (m, 2H), 7.21 – 7.17 (m, 3H), 7.01 (d, $J = 7.5$ Hz, 1H), 5.00 (s, 2H), 4.45 (s, 2H), 4.44 (s, 2H), 2.37 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 164.8, 142.1, 141.1, 133.3, 133.1, 132.8, 130.2, 130.0, 129.3, 128.9, 128.3, 127.9, 127.8, 127.6, 127.3, 127.2, 126.5, 126.4, 126.3, 125.8, 125.0, 53.3, 50.9, 33.9, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{25}\text{N}_2\text{O}_2\text{S}$ 441.1637; found 441.1639.

(E)-4-methyl-N-(2-pentyl-1,4-dihydroisoquinolin-3(2H)-ylidene)benzenesulfonamide (5k):


Prepared according to the general procedure **C** from *2-pentylisoquinolin-2-ium bromide (4k)* (84 mg, 0.3 mmol). Flash column chromatography (22-25% EtOAc/Hex) afforded the desired product **5k** as a yellow solid (85.4 mg, 0.23 mmol, 77% yield). Reaction time: 15 h. Reaction temperature: 80 °C. Melting point: 148-150 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.84 (d, $J = 8.2$ Hz, 2H), 7.30 – 7.22 (m, 5H), 7.15 (d, $J = 6.7$ Hz, 1H), 4.47 (s, 2H), 4.32 (s, 2H), 3.62 – 3.58 (m, 2H), 2.39 (s, 3H), 1.64 – 1.57 (m, 2H), 1.31 – 1.21 (m, 4H), 0.84 (t, $J = 6.9$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 164.1, 141.9, 141.4, 130.5, 130.3, 129.2, 128.3, 127.6, 127.2, 126.3, 124.9, 51.6, 50.5, 33.8, 29.0, 26.3, 22.4, 21.5, 13.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{27}\text{N}_2\text{O}_2\text{S}$ 371.1793; found 371.1796.

(E)-N-(2-allyl-1,4-dihydroisoquinolin-3(2H)-ylidene)-4-methylbenzenesulfonamide (5l):


Prepared according to the general procedure **C** from *2-allylisoquinolin-2-ium bromide (4l)* (75 mg, 0.3 mmol). Flash column chromatography (25-27% EtOAc/Hex) afforded the desired product **5l** as a yellow solid (98 mg, 0.287 mmol, 96% yield). Reaction time: 15 h. Melting point: 130-132 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.84 (d, $J = 8.2$ Hz, 2H), 7.29 – 7.22 (m, 5H), 7.13 (d, $J = 7.1$ Hz, 1H), 5.81 – 5.73 (m, 1H), 5.23 – 5.20 (m, 1H), 5.19 – 5.15 (m, 1H), 4.44 (s, 2H), 4.35 (s, 2H), 4.25 (d, $J = 6.0$ Hz, 2H), 2.39 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 164.4, 142.1, 141.2, 130.9, 130.3, 130.1, 129.3, 128.3, 127.6, 127.2, 126.4, 125.0, 119.1, 52.4, 50.7, 33.8, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2\text{S}$ 341.1324; found 341.1322.

(E)-4-methyl-N-(2-phenethyl-1,4-dihydroisoquinolin-3(2H)-ylidene)benzenesulfonamide (5m):


Prepared according to the general procedure **C** from *2-phenethylisoquinolin-2-ium bromide (4m)* (94 mg, 0.3 mmol). Flash column chromatography (28-30% EtOAc/Hex) afforded the desired product **5m** as a yellow solid (106.4 mg, 0.263 mmol, 88% yield). Reaction time: 30 h. Melting point: 144-145 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.88 (d, $J = 8.1$ Hz, 2H), 7.28 – 7.25 (m, 3H), 7.23 – 7.18 (m, 5H), 7.05 – 7.03 (m, 2H), 6.97 (d, $J = 7.4$ Hz, 1H), 4.33 (s, 2H), 4.26 (s, 2H), 3.79 (t, $J = 7.3$ Hz, 2H), 2.90 (t, $J = 7.3$ Hz, 2H), 2.41 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 164.1, 142.1, 141.4, 138.4, 130.5, 130.2, 129.3, 128.9, 128.8, 128.2, 127.6, 127.1, 126.7, 126.4, 125.0, 52.8, 52.7, 33.9, 33.0, 21.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_2\text{S}$ 405.1637; found 405.1635.

(E)-N-(2-benzyl-4-(3-oxobutyl)-1,4-dihydroisoquinolin-3(2H)-ylidene)-4-methylbenzenesulfonamide (5n):


Prepared according to the general procedure **C** from *2-benzyl-4-(3-oxobutyl)isoquinolin-2-ium bromide (4n)* (111 mg, 0.3 mmol). Flash column chromatography (5-95% Acetone/DCM) afforded the desired product **5n** as a sticky pale yellow solid (116 mg, 0.25 mmol, 84% yield). Reaction time: 19 h. $R_f = 0.3$ (acetone/DCM 1:19). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.77 (d, $J = 8.2$ Hz, 2H), 7.28 – 7.25 (m, 4H), 7.24 – 7.18 (m, 4H), 7.15 – 7.13 (m, 2H), 7.06 (d, $J = 7.3$ Hz, 1H), 4.93 (dd, $J = 10.1, 4.9$ Hz, 1H), 4.80 (s, 2H), 4.68 (d, $J = 16.2$ Hz, 1H), 4.24 (d, $J = 16.2$ Hz, 1H), 2.78 – 2.70 (m, 1H), 2.48 – 2.39 (m, 1H), 2.36 (s, 3H), 2.34 – 2.28 (m, 1H), 2.08 (s, 3H), 1.92 – 1.82 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 207.6, 167.4, 142.0, 141.3, 135.3, 134.3, 131.1, 129.2, 128.9, 128.1, 128.0, 128.0, 127.9, 127.4, 126.2, 125.6, 53.3, 50.5, 43.8, 40.9, 30.0, 26.6, 21.5. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{29}\text{N}_2\text{O}_3\text{S}$ 461.1899; found 461.1900.

(E)-N-(2-benzyl-1,4-dihydroisoquinolin-3(2H)-ylidene)benzenesulfonamide (5o):


Prepared according to the general procedure **C** from *2-benzylisoquinolin-2-ium bromide* (**4a**) (75 mg, 0.25 mmol) and *benzenesulfonyl azide* (**4o**) (91.6 mg, 0.5 mmol) Flash column chromatography (28-30% EtOAc/Hex) afforded the desired product **5o** as a pale yellow solid (92 mg, 0.235 mmol, 94% yield). Reaction time: 18 h. Melting point: 147-148 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.95 – 7.93 (m, 2H), 7.50 – 7.47 (m, 1H), 7.45 – 7.42 (m, 2H), 7.29 – 7.25 (m, 5H), 7.23 – 7.19 (m, 3H), 7.05 (d, $J = 7.5$ Hz, 1H), 4.86 (s, 2H), 4.43 (s, 2H), 4.42 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 164.9, 143.9, 135.2, 131.7, 130.2, 129.9, 128.9, 128.7, 128.4, 128.2, 128.1, 127.7, 127.3, 126.4, 125.0, 53.3, 50.9, 33.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{O}_2\text{S}$ 377.1324; found 377.1319.

(E)-N-(2-benzyl-1,4-dihydroisoquinolin-3(2H)-ylidene)-4-isopropylbenzenesulfonamide (5p):


Prepared according to the general procedure **C** from *2-benzylisoquinolin-2-ium bromide* (**4a**) (90 mg, 0.3 mmol) and *4-isopropylbenzenesulfonyl azide* (**4p**) (135 mg, 0.6 mmol) Flash column chromatography (20-22% EtOAc/hexane) afforded the desired product **5p** as a yellow solid (91 mg, 0.217 mmol, 72% yield). Reaction time: 15 h. Melting point: 134-135 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.86 (d, $J = 8.3$ Hz, 2H), 7.29 – 7.26 (m, 5H), 7.25 – 7.19 (m, 5H), 7.04 (d, $J = 7.4$ Hz, 1H), 4.86 (s, 2H), 4.43 (s, 2H), 4.41 (s, 2H), 2.98 – 2.91 (m, 1H), 1.25 (d, $J = 6.9$ Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 164.8, 152.9, 141.3, 135.3, 130.2, 130.0, 128.9, 128.3, 128.2, 128.1, 127.6, 127.2, 126.8, 126.5, 125.0, 53.2, 50.8, 34.2, 33.9, 23.8. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{27}\text{N}_2\text{O}_2\text{S}$ 419.1793; found 419.1791.

(E)-N-(4-(N-(2-benzyl-1,4-dihydroisoquinolin-3(2H)-ylidene)sulfamoyl)phenyl)acetamide (5q):


Prepared according to the general procedure **C** from *2-benzylisoquinolin-2-ium bromide* (**4a**) (90 mg, 0.3 mmol) and *4-acetamidobenzenesulfonyl azide* (**4q**) (144 mg, 0.6 mmol) Flash column chromatography (6-94% acetone/DCM) afforded the desired product **5q** as a white solid (113 mg, 0.260 mmol, 87% yield). Reaction time: 15 h. Melting point: 130-132 °C. $R_f = 0.3$ (1-9% acetone/DCM). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.35 (brs, 1H), 7.78 (d, $J = 8.7$ Hz, 2H), 7.58 (d, $J = 8.4$ Hz, 2H), 7.28 – 7.24 (m, 4H), 7.22 – 7.16 (m, 4H), 7.04 (d, $J = 7.3$ Hz, 1H), 4.83 (s, 2H), 4.41 (s, 2H), 4.33 (s, 2H), 2.14 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 169.2, 164.9, 141.5, 138.4, 134.9, 130.1, 129.6, 129.0, 128.4, 128.2, 128.0, 127.5, 127.3, 127.3, 125.0, 119.4, 53.2, 51.0, 33.7, 24.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{24}\text{N}_3\text{O}_3\text{S}$ 434.1538; found 434.1537.

(E)-N-(2-benzyl-1,4-dihydroisoquinolin-3(2H)-ylidene)naphthalene-2-sulfonamide (5r):


Prepared according to the general procedure **C** from *2-benzylisoquinolin-2-ium bromide* (**4a**) (90 mg, 0.3 mmol) and *naphthalene-2-sulfonyl azide* (**4r**) (144 mg, 0.6 mmol) Flash column chromatography (22-25% EtOAc/Hex) afforded the desired product **5r** as a yellow solid (121 mg, 0.284 mmol, 94% yield). Reaction time: 20 h. Melting point: 133-134 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.49 (br, 1H), 7.93 – 7.85 (m, 4H), 7.59 – 7.53 (m, 2H), 7.28 – 7.24 (m, 5H), 7.22 – 7.18 (m, 3H), 7.05 (d, $J = 7.5$ Hz, 1H), 4.86 (s, 2H), 4.49 (s, 2H), 4.43 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 164.8, 140.9, 135.2, 134.5, 132.3, 130.1, 129.9, 129.3, 128.9, 128.9, 128.3, 128.2, 128.1, 128.1, 127.9, 127.7, 127.3, 127.2, 126.7, 125.0, 122.8, 53.3, 51.0, 33.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{23}\text{N}_2\text{O}_2\text{S}$ 427.1480; found 427.1473.

(E)-N-(2-benzyl-1,4-dihydroisoquinolin-3(2H)-ylidene)-5-chlorothiophene-2-sulfonamide (5s):

Prepared according to the general procedure **C** from *2-benzylisoquinolin-2-ium bromide* (**4a**) (90 mg, 0.3 mmol) and *5-chlorothiophene-2-sulfonyl azide* (**4s**) (134 mg, 0.6 mmol). Flash column chromatography (22-25% EtOAc/Hex) afforded the desired product **5s** as a yellow solid (70 mg, 0.168 mmol, 56% yield). Reaction time: 20 h. Melting point: 185-186 °C. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.39 (d, $J = 3.9$ Hz, 1H), 7.33 – 7.30 (m, 3H), 7.28 – 7.25 (m, 4H), 7.23 – 7.21 (m, 1H), 7.06 (d, $J = 7.4$ Hz, 1H), 6.84 (d, $J = 3.9$ Hz, 1H), 4.90 (s, 2H), 4.44 (s, 2H), 4.41 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 164.9, 143.6, 135.5, 134.9, 129.8, 129.5, 129.1, 128.5, 128.3, 128.2, 127.6, 127.4, 126.1, 125.1, 53.4, 50.9, 33.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{18}\text{ClN}_2\text{O}_2\text{S}_2$ 417.0498; found 417.0493.


(E)-N-(2-benzyl-1,4-dihydroisoquinolin-3(2H)-ylidene)-1-methyl-1H-imidazole-4-sulfonamide (5t):

Prepared according to the general procedure **C** from *2-benzylisoquinolin-2-ium bromide* (**4a**) (90 mg, 0.3 mmol) and *1-methyl-1H-imidazole-4-sulfonyl azide* (**4t**) (112 mg, 0.6 mmol). Flash column chromatography (10-90% acetone/DCM) afforded the desired product **5t** as a yellow solid (62 mg, 0.163 mmol, 54% yield). Reaction time: 15 h. Melting point: 214-216 °C. $R_f = 0.3$ (1-9% acetone/DCM). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.42 – 7.41 (m, 2H), 7.34 – 7.27 (m, 7H), 7.24 – 7.21 (m, 1H), 7.05 (d, $J = 7.5$ Hz, 1H), 4.93 (s, 2H), 4.63 (s, 2H), 4.41 (s, 2H), 3.70 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 166.1, 144.4, 138.2, 135.4, 130.5, 130.3, 128.9, 128.3, 128.2, 127.9, 127.7, 127.1, 124.9, 122.2, 53.1, 50.7, 34.1, 33.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{21}\text{N}_4\text{O}_2\text{S}$ 381.1385; found 381.1381.

N-((E)-2-benzyl-1,4-dihydroisoquinolin-3(2H)-ylidene)-1-((1S,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonamide (5u):


Prepared according to the general procedure **C** from *2-benzylisoquinolin-2-ium bromide* (**4a**) (90 mg, 0.3 mmol) and **4u** (154 mg, 0.6 mmol). Flash column chromatography (20-22% EtOAc/hexane) afforded the desired product **5u** as a sticky yellow solid (95.4 mg, 0.211 mmol, 70% yield). Reaction time: 15 h. $R_f = 0.3$ (EtOAc/Hex 3:7). $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.36 – 7.33 (m, 2H), 7.31 – 7.28 (m, 3H), 7.24 – 7.23 (m, 3H), 7.07 (d, $J = 7.4$ Hz, 1H), 4.96 – 4.84 (m, 2H), 4.55 – 4.51 (m, 1H), 4.48 – 4.39 (m, 3H), 3.71 (d, $J = 14.9$ Hz 1H), 3.03 (d, $J = 14.9$ Hz 1H), 2.66 – 2.60 (m, 1H), 2.35 – 2.30 (m, 1H), 2.05 (t, $J = 4.4$ Hz, 1H), 1.99 – 1.94 (m, 1H), 1.84 (d, $J = 18.3$ Hz 1H), 1.63 – 1.57 (m, 1H), 1.32 – 1.28 (m, 2H), 1.11 (s, 3H), 0.86 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 215.4, 164.9, 135.4, 130.3, 130.2, 128.9, 128.3, 127.9, 127.6, 127.2, 124.9, 58.4, 52.8, 51.4, 50.9, 48.1, 42.8, 42.6, 34.0, 27.1, 24.3, 20.0, 19.9. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{31}\text{N}_2\text{O}_3\text{S}$ 451.2055; found 451.2053.

10. Applications and Synthetic transformations**10.1. Gram scale synthesis of 3a:**



To an oven-dried Schlenk tube, was charged with **1a** (1.44 g, 4.8 mmol, 1.0 equiv.) and Tosyl azide (1.97 g, 2.0 equiv.), and exchanged with nitrogen and vacuum three times. To this was added NEt_3 (1.4 mL, 2.0 equiv.), and 30 mL of MeCN followed by HCOOH (56 μL , 5.0 equiv). The reaction mixture was heated to 80 $^\circ\text{C}$ for 24 hours. After the completion of the reaction (monitored by TLC), the reaction was quenched with a K_2CO_3 aqueous solution after being diluted with EtOAc. The organic phase was separated, and the aqueous phase was extracted with EtOAc. The combined organic phase was washed with H_2O and dried over Na_2SO_4 . The solvent was removed under reduced pressure. The resulting residue was purified by column chromatography on silica gel (PE/EA = 4:1) to give the corresponding product (1.25 g, 3.2 mmol, 67%).

10.2. General Procedure D for the Synthesis of 1-benzyl-3,4-dihydroquinolin-2(1H)-one (**6a**)




To a stirred solution of **3a** (100 mg, 0.25 mmol, 1.0 equiv.) in MeOH (3 mL) was added K_2CO_3 (106 mg, 3.0 equiv.) and heated at 65 $^\circ\text{C}$ for 12 h. The solvent was evaporated under reduced pressure. The resultant residue was dissolved in ethyl acetate, washed with H_2O , dried over Na_2SO_4 , filtered and concentrated under reduced pressure to afford the crude product which was purified by silica gel column chromatography (10-12% ethyl acetate/hexane) to afford the desired product **6a** as a white solid (56.7 mg, 0.24 mmol, 98%). R_f = 0.35 (EtOAc/Hex 1:4).

^1H NMR (500 MHz, CDCl_3): δ 7.29 – 7.26 (m, 2H), 7.21 – 7.19 (m, 3H), 7.14 (d, J = 7.4 Hz, 1H), 7.09 – 7.06 (m, 1H), 6.94 (td, J = 7.4, 0.8 Hz, 1H), 6.86 (d, J = 8.1 Hz, 1H), 5.17 (s, 2H), 2.97 – 2.94 (m, 2H), 2.78 – 2.75 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 170.6, 139.9, 137.1, 128.8, 127.9, 127.5, 127.1, 126.4, 126.4, 122.9, 115.6, 46.2, 31.9, 25.6. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{16}\text{NO}$ 238.1232; found 238.1231.

However, the hydrolysis of **5a** was not successful under the present conditions.


10.3. Step-wise synthesis of 1-benzyl-3,4-dihydroquinolin-2(1H)-one (6a)



Step 1: In an oven-dried Schlenk tube, was charged with **1a** (3.0 g, 10 mmol, 1.0 equiv.) and Tosyl azide (3.94 g, 2.0 equiv.), and exchanged with nitrogen and vacuum three times. Then, 2.8 mL (2.0 equiv) of Et₃N and MeCN (60 mL) were added. The reaction mixture was heated to 80 °C for 24 hours after the addition of 1.9 mL (5.0 equiv) of HCOOH. After the completion of the reaction (monitored by TLC), the reaction was quenched with a K₂CO₃ aqueous solution after being diluted with EtOAc. The organic phase was separated, and the aqueous phase was extracted with EtOAc. The combined organic phase was washed with H₂O and dried over Na₂SO₄. The solvent was removed under reduced pressure. The resulting residue was washed with HPLC hexane to remove excess TsN₃, dried, and processed for the next step without column purification.

Step 2: To a stir solution of the above reaction mixture in MeOH (25 mL) was added K₂CO₃ (3.0 equiv) and heated at 65 °C for 12 h. The solvent was evaporated under reduced pressure. The resultant residue was dissolved in ethyl acetate, washed with H₂O, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude mixture was purified by silica gel column chromatography (10-12% ethyl acetate/hexane) to afford the desired product **6a** as a sticky white solid (1.96 g, 8.26 mmol, 82%).


10.4. Gram scale synthesis of 1-(3-(trifluoromethyl)benzyl)-3,4-dihydroquinolin-2(1H)-one (6w)



Step 1: The compound **3w** was prepared according to the general procedure **C** from **1w** (174 mg, 0.47 mmol). The resulting residue was washed with HPLC hexane to remove excess TsN₃, dried, and processed for the next step without purification.


Step 2: To stir solution of the above reaction mixture in MeOH (4-5 mL) was added K₂CO₃ (3.0 equiv) and heated at 65 °C for 12 h. The reaction was evaporated under reduced pressure. The resultant residue was dissolved in ethyl acetate, washed with H₂O, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude mixture was purified by silica gel column chromatography (10-12% ethyl acetate/hexane) to afford the desired product **6w** as a white solid (110 mg, 0.36 mmol, 76%). Melting point: 128-129 °C. ¹H NMR (400 MHz, CDCl₃): δ 7.50 – 7.48 (m, 2H), 7.43 – 7.36 (m, 2H), 7.18 (d, *J* = 7.3 Hz, 1H), 7.14 – 7.09 (m, 1H), 7.01 – 6.97 (m, 1H), 6.80 (d, *J* = 8.1 Hz, 1H), 5.22 (s, 2H), 3.01 – 2.97 (m, 2H), 2.82 – 2.78 (m, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 170.7, 139.7, 138.3, 131.2 (q, *J* = 32.3 Hz), 129.8, 129.4, 128.2, 127.7, 126.5, 124.1 (q, *J* = 272.3 Hz), 124.1 (q, *J* = 3.7 Hz), 123.4 (q, *J* = 3.9 Hz), 123.3, 115.4, 46.0, 31.9, 25.6. ¹⁹F NMR (376 MHz, CDCl₃): δ -62.6. HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₇H₁₅F₃NO 306.1106; found 306.1103.

10.5. Synthesis of 1-benzyl-3-(4-bromobenzylidene)-3,4-dihydroquinolin-2(1H)-one (**8**):⁸




To a stirred solution of **6a** (100 mg, 0.42 mmol, 1 equiv.) and **7** (2.5 equiv.) in 3 mL EtOH, was added t-BuOK (1.2 equiv.) slowly and the reaction was refluxed at 80 °C for 24 h. Another 1.5 equiv. of aldehyde **7** was added (**6a** was not full converted) after 24 h, and the mixture was refluxed for another 12 h. After cooling to 0 °C, the reaction was quenched with saturated NH₄Cl and diluted with EtOAc and washed with water and brine (3×100 mL), dried over anhydrous Na₂SO₄, and evaporated under reduced pressure. The residue was purified by column chromatography (10% EtOAc/ hexane) to afford the desired product **8** as a yellow oil (77 mg, 0.19 mmol, 45%). ¹H NMR (400 MHz, CDCl₃): δ 7.45 (d, *J* = 8.1 Hz, 3H), 7.38 – 7.34 (m, 2H), 7.29 – 7.24 (m, 3H), 7.22 – 7.18 (m, 5H), 7.16 – 7.12 (m, 1H), 5.56 (s, 2H), 3.97 (s, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 162.4, 138.7, 138.3, 136.6, 136.5, 132.8, 131.8, 131.3, 129.9, 128.9, 128.5, 127.4, 126.7, 122.3, 120.8, 120.4, 114.9, 46.5, 36.7. HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₂₃H₁₉NOBr 404.0650; found 404.0645.

10.6. Synthesis of 1-benzylquinolin-2(1H)-one (**9**):




To a solution of **6a** (100 mg, 0.42 mmol, 1 equiv.) in chlorobenzene (2.0 mL) was added NBS (74 mg, 1 equiv.) and AIBN (14 mg, 0.2 equiv.), and refluxed for 4 h. To this was added further AIBN (0.2 equiv.) and NBS (0.1 equiv.) and heated for 20 h. The reaction mixture was cooled, filtered, washed with DCM, and concentrated. The crude product was purified by silica gel column chromatography (18-20% EtOAc/hexane) to afford the desired product **9** as a yellow oil (93 mg, 0.39 mmol, 94%). ¹H NMR (400 MHz, CDCl₃): δ 7.71 (d, *J* = 9.5 Hz, 2H), 7.53 (dd, *J* = 7.7, 1.1 Hz, 2H), 7.41 – 7.37 (m, 1H), 7.29 – 7.25 (m, 3H), 7.23 – 7.19 (m, 3H), 7.17 – 7.14 (m, 1H), 6.79 (d, *J* = 9.5 Hz, 1H), 5.54 (s, 2H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 162.5, 139.6, 139.5, 136.4, 130.7, 128.9, 128.8, 127.3, 126.6, 122.2, 121.6, 120.9, 115.1, 45.9. HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₆H₁₄NO 236.1075; found 236.1069.

10.7. Synthesis of 3,4-dihydroquinolin-2(1H)-one (10):⁸



Trifluoromethanesulfonic acid (2.0 mL, 4.0 equiv.) was added to a solution of **6a** (1.3 g, 5.48 mmol, 1 equiv.) in toluene (8 mL). The mixture was heated at 130 °C for 30 h. Then the reaction mixture was poured into aqueous NaHCO₃, extracted with EtOAc, and washed with brine solution. The combined organic fraction was dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford the crude product which was purified by silica gel column chromatography (3% acetone/DCM) to afford the desired product **10** as a brown solid (754 mg, 5.13 mmol, 93%). Melting Point: 168-169 °C. ¹H NMR (500 MHz, CDCl₃): δ 9.60 (s, 1H), 7.19 – 7.16 (m, 2H), 7.01 – 6.98 (m, 1H), 6.89 (d, *J* = 7.8 Hz, 1H), 2.99 – 2.98 (m, 2H), 2.68 – 2.65 (m, 2H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 172.6, 137.5, 127.9, 127.6, 123.7, 123.1, 115.7, 30.8, 25.4. HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₉H₁₀NO 148.0762; found 148.0759.

10.8. Synthesis of CYP11B2 inhibitor 14



Step 1: Synthesis of 1-benzyl-6-bromo-3,4-dihydroquinolin-2(1H)-one (6e)


6e was prepared according to the general procedure **D** from **3e** (151 mg, 0.32 mmol). Flash column chromatography (18-20% EtOAc/hexane) afforded the desired product **6e** as a sticky white solid (94.1 mg, 0.29 mmol, 93% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.31 – 7.27 (m, 3H), 7.25 – 7.17 (m, 4H), 6.73 (d, *J* = 8.7 Hz, 1H), 5.14 (s, 2H), 2.96 – 2.93 (m, 2H), 2.79 – 2.75 (m, 2H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 170.1, 139.1, 136.6, 130.8, 130.3, 128.9, 128.6, 127.3, 126.5, 117.3, 115.7, 46.2, 31.6, 25.4. HRMS (ESI) *m/z*: [M+H]⁺ calcd for C₁₆H₁₅NOBr 316.0337; found 316.0337.

Step 2: Synthesis of 1-benzyl-6-(pyridin-3-yl)-3,4-dihydroquinolin-2(1H)-one (14)

A reaction tube was charged with **6e** (66 mg, 0.21 mmol), **13** (45 mg, 0.35 mmol), Na₂CO₃ (153 mg, 6 equiv), and Pd(PPh)₄ (20 mg, 7 mol%). To this was added toluene (1.5 mL), water (1 mL), and EtOH (0.5 mL) under a nitrogen atmosphere, and the mixture was refluxed at 120 °C for 24 h. Thereafter reaction mixture was cooled, and filtered through a plug of celite. The resulting mixture was diluted with water and extracted with ethyl acetate. The combined extracts were dried over Na₂SO₄, concentrated, and purified by flash chromatography on silica gel (Acetone/DCM, 4:96%) to afford the desired CYP11B2 inhibitors **14** as a white solid (59.7 mg, 0.19 mmol, 90%). ¹H NMR (400 MHz, CDCl₃): δ 8.78 (d, *J* = 1.8 Hz, 1H), 8.55 (dd, *J* = 4.8, 1.5 Hz, 1H), 7.81 – 7.78 (m, 1H), 7.39 (d, *J* = 1.9 Hz, 1H), 7.34 – 7.30 (m, 4H), 7.26 – 7.22 (m, 3H), 6.97 (d, *J* = 8.4 Hz, 1H), 5.22 (s, 2H), 3.08 – 3.05 (m, 2H), 2.86 – 2.82 (m, 2H). ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 170.4, 148.4, 148.0, 140.0, 136.9, 135.8, 134.0, 132.5, 128.9, 127.3, 127.2, 126.6, 126.5, 126.2, 123.7,

116.3, 46.2, 31.9, 25.8. **HRMS** (ESI) m/z : $[M+H]^+$ calcd for $C_{21}H_{19}N_2O$ 315.1497; found 315.1497. The analytical data of the compound are in accordance with the literature.⁹

10.9. Synthesis of D₄R antagonist **18**¹⁰



Step 1: Synthesis of 1-(3-bromopropyl)-3,4-dihydroquinolin-2(1H)-one (**16**)

A solution of **10** (100 mg, 0.68 mmol) in DMF was added dropwise to a suspension of NaH (1.5 equiv.) in DMF (1.5 mL). The resulting mixture was stirred at room temperature for 20 min., followed by the addition of a solution of **15** (1.1 equiv.) in DMF (0.5 mL), and the resulting mixture was stirred at room temperature for 1 h. After that, the mixture was diluted with water and extracted with ethyl acetate. The combined extracts were dried over Na_2SO_4 , concentrated, and purified by flash chromatography on silica gel (eluent: 10:90% EtOAc/hexane) to afford the desired **16** as a brown oil (106 mg, 0.39 mmol, 58%). **¹H NMR (400 MHz, $CDCl_3$)**: δ 7.28 – 7.24 (m, 1H), 7.17 (d, $J = 7.3$ Hz, 1H), 7.07 (d, $J = 8.0$ Hz, 1H), 7.01 (td, $J = 7.4, 0.9$ Hz, 1H), 4.10 – 4.07 (m, 2H), 3.47 (t, $J = 6.5$ Hz, 2H), 2.91 – 2.88 (m, 2H), 2.66 – 2.63 (m, 2H), 2.27 – 2.20 (m, 2H). **¹³C{¹H} NMR (100 MHz, $CDCl_3$)**: δ 170.5, 139.5, 128.2, 127.7, 126.6, 123.1, 114.7, 41.3, 31.9, 30.9, 30.4, 25.6. **HRMS** (ESI) m/z : $[M+H]^+$ calcd for $C_{12}H_{15}BrNO$ 268.0337; found 268.0338.


Step 2: Synthesis of 1-(3-(4-(4-chlorophenyl)piperazin-1-yl)propyl)-3,4-dihydroquinolin-2(1H)-one (**18**)

To a solution of **16** (85 mg, 0.32 mmol) in DMF (1.5 mL) was added a solution of **17** (94 mg, 1.5 equiv) in dropwise followed by K_2CO_3 (66 mg, 1.5 equiv.) in DMF (1.5 mL). The reaction mixture was stirred at 80 °C for 12 h; then, it was diluted with water (20 mL) and extracted with EtOAc (2× 20 mL). The organic layer was washed with brine and dried over anhydrous Na_2SO_4 . The evaporation of the solvent under reduced pressure afforded a residue, which was purified by flash chromatography, (eluent: 6:94% MeOH/DCM) to afford the desired D₄ antagonist **18** as a white solid (94 mg, 0.24 mmol, 76%). **¹H NMR (400 MHz, $CDCl_3$)**: δ 7.18 – 7.08 (m, 4H), 7.02 (d, $J = 8.0$ Hz, 1H), 6.94 – 6.91 (m, 1H), 6.76 (d, $J = 9.0$ Hz, 2H), 3.96 – 3.92 (m, 2H), 3.10 – 3.08 (m, 4H), 2.83 – 2.79 (m, 2H), 2.59 – 2.51 (m, 6H), 2.40 (t, $J = 7.1$ Hz, 2H), 1.84 – 1.77 (m, 2H). **¹³C{¹H} NMR (100 MHz, $CDCl_3$)**: δ 170.3, 149.9, 139.7, 128.9, 128.1, 127.5, 126.6, 124.5, 122.8, 117.2, 114.9, 55.7, 53.1, 49.2, 40.5, 32.0, 25.7, 24.7. **HRMS** (ESI) m/z : $[M+H]^+$ calcd for $C_{22}H_{27}ClN_3O$ 384.1843; found 384.1832.

11. Control Experiments


11.1. Palladium Scavenging Experiments:¹¹

Biotage ISOLUTE Si-TMT scavenging resin, which is highly efficient to remove trace amounts of palladium, rhodium, ruthenium, nickel, and platinum, was applied to quinolinium and isoquinolinium substrates. These substances showed no change in reactivity after treatment.




1a and **2a** (200 mg) was dissolved in MeOH (5 mL) and Biotage ISOLUTE Si-TMT scavenging resin (40 mg, 20% w/w) was added and the solution was stirred at room temperature for 3 h. The solution was filtered and concentrated in vacuo to return “purified” **1a** and **4a**. These substrates were subjected to the standard reaction conditions utilizing new glassware and gave **3a** and **5a** in 69% and 88% (16 hours) NMR yield, respectively indicating no loss of reactivity.

11.2. Synthesis of Quinoline 1-oxide-2-d1 and Quinoline-2-d1:¹²




Step 1: Quinoline N-oxide (500 mg, 3.4 mmol), D₂O (3 mL) and NaOH (344 mg, 2.5 equiv) were weighed into a pressure vial sealed with a Teflon cap. The reaction mixture was stirred at 95 °C in an oil bath for 36 h. After cooling to room temperature, the mixture was then extracted with ethyl acetate (3×10 mL), washed with saturated NaCl solution (3×5 mL), dried over Na₂SO₄, and filtered. Ethyl acetate was under reduced pressure to obtain the crude **2-d1-quinoline N-oxide** product which was employed for the next step without further purification (471 mg, 94%). ¹H NMR (400 MHz, CDCl₃): δ 8.76 (d, *J* = 8.7 Hz, 1H), 8.54 (d, *J* = 5.5 Hz, 0.093 H), 7.87 (d, *J* = 8.1 Hz, 1H), 7.79 – 7.74 (m, 2H), 7.65 (t, *J* = 7.3 Hz, 1H), 7.31 – 7.28 (m, 1H).





Step 2: 2-d1-Quinoline N-oxide (471 mg, 3.22 mmol) was dissolved in toluene in round bottom flask with stirring at room temperature. To this, PCl_3 (530 mg, 1.3 equiv) was added, and stirred at 50 °C for 3 h. Saturated NaHCO_3 was added to the reaction mixture, and extracted with ethyl acetate, washed with saturated NaCl , dried over anhydrous Na_2SO_4 , filtered, and evaporated. The crude mixture was purified by column chromatography on silica gel (20% ethyl acetate in hexane) to give **quinoline-2-d1** (288 mg, 69%).


11.3. Synthesis of 1-benzylquinolin-1-ium-2-d1 bromide (**1a-d**):



The representative general procedure **B** was followed, using **quinoline-2-d1** (260 mg, 2.0 mmol) under reflux for 24 h to give **1a-d** (540 mg, 89%) as an off-white solid. $^1\text{H NMR}$ (400 MHz, DMSO-d_6): δ 9.88 (s, 0.092H), 9.44–9.42 (m, 1H), 8.56–8.53 (m, 2H), 8.32 (d, $J = 8.4$ Hz, 1H), 8.23–8.19 (m, 1H), 8.04–8.00 (m, 1H), 7.43–7.34 (m, 5H), 6.45 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO-d_6): δ 150.0 (t, $J = 25.8$ Hz), 149.7, 148.2, 137.4, 135.7, 133.8, 130.8, 129.9, 129.8, 129.0, 128.7, 122.3, 119.3, 59.7. HRMS (ESI) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{13}\text{DN}$ 221.1184; found 221.1182.




11.4. Synthesis of 1-benzyl-1,2-dihydroquinoline (A):¹³




To a suspension of 1-benzylquinolin-1-ium bromide **1a** (0.5 g, 1.66 mmol) in 5 mL of THF was slowly added lithium aluminium hydride (69 mg, 1.1 equiv.) at room temperature. The reaction was stirred at room temperature for 20 min, then slowly quenched with 0.1 mL of water and stirred for an additional 10 min. To the reaction was added 0.2 mL 10% sodium hydroxide solution and stirred at room temperature for an additional 10 min. To the reaction mixture was added 5% Na₂CO₃ solution and extracted with ethyl acetate, dried with anhydrous sodium sulfate, and then concentrated by removing the solvent under vacuum to give the unstable crude 1-benzyl-1,2-dihydroquinoline as a yellow oil (350 mg, 1.58 mmol, 95%). This oil was used immediately in our mechanistic investigations.

11.5. Control experiments without base and formic acid:




Under the standard conditions, the control experiments were performed. When the reaction was performed without Et₃N, **3a** was not detected. However, without formic acid, **3a''** is obtained in 60% yield.

11.6. Control experiment without azide:¹³




Without the TsN₃, the reaction was performed under the standard conditions. The simple hydrogenation product **3a'** is obtained in 53% yield.

11.7. Control experiments with possible intermediates **3a''** and **A**:




Possible intermediates **3a''** and **A** were subjected to standard conditions following the general procedure C. The desired product **3a** is formed in 60% yield with **A** whereas no product was detected with **3a''**.

11.8. Radical trapping reaction





The reaction between **1a** and **2a** was performed along with TEMPO (2 equiv.) and BHT (2 equiv.) under standard conditions following the general procedure C. After completion of the reaction, the NMR yields were calculated. In the presence of TEMPO, the yield of **3a** was 73% and in the presence of BHT, the yield of **3a** was 76%.

11.9. Deuterium labelling experiment 1




The reaction between **1a** and **2a** was performed with DCO₂D (5 equiv.) under standard conditions following the general procedure C. After completion of the reaction, the deuterium incorporation was calculated from the isolated product **3a-d2** by NMR analysis.








11.10. Deuterium labelling experiment 2




The reaction between **4a** and **2a** was performed with DCO_2D (5 equiv.) under standard conditions following the general procedure C. After completion of the reaction, the deuterium incorporation was calculated from the isolated product **3a-d1** by NMR analysis.




11.11. Deuterium labelling experiment 3




The reaction between **1a-d** and **2a** was performed with HCO₂H (2 equiv.) under standard conditions following the general procedure C. After completion of the reaction, the deuterium incorporation was calculated from the isolated product **3a-d2** by NMR analysis.







11.12. Deuterium labelling experiment 4



The reaction between **1a-d** and **2a** was performed with DCO₂D (5 equiv.) under standard conditions following the general procedure C. After completion of the reaction, the deuterium incorporation was calculated from the isolated product **3a-d₂** by NMR analysis.



12. Crystal Structure of 3q and 5a

X-Ray Data Collection and Structure Refinement Details:

A good quality single crystals of size 0.95 x 0.09 x 0.04 mm and 0.16 x 0.10 x 0.08 mm, were selected under a polarizing microscope and was mounted on a glass fiber for data collection. Single crystal X-ray data for compounds **3q** and **5a** were collected on the Rigaku XtaLAB Synergy-S single crystal X-ray diffractometer equipped with a HyPix-6000HE Hybrid Photon Counting (HPC) detector and dual Mo and Cu microfocus sealed X-ray source with kappa goniometer at 293 (2) K. Data collection cell determination, and data reduction was performed using the CrysAlisPro¹ software. Structure solution and refinement were performed by using SHELX-97². Refinement of coordinates and anisotropic thermal parameters of non-hydrogen atoms were carried out by the full-matrix least-squares method. The hydrogen atoms attached to carbon atoms were generated with idealized geometries and isotropically refined using a riding model.

1. CrysAlisPro, Oxford Diffraction /Agilent Technologies UK Ltd, Yarnton, England.
2. Sheldrick, G. M. Acta Crystallogr. Sect. A 2008, 64, 112–122.




Table 1 Crystal data and structure refinement details for **3q**.

Compound	3q	5a
Empirical formula	C ₂₁ H ₂₆ N ₂ O ₂ S	C ₂₃ H ₂₂ N ₂ O ₂ S
Formula weight	370.50	390.49
Crystal System	Monoclinic	Orthorhombic
Space group	P 2 ₁ /c	P b c a
<i>a</i> (Å)	8.68400(10)	15.7372(4)
<i>b</i> (Å)	16.4916(4)	13.4885(2)
<i>c</i> (Å)	13.6197(2)	18.8423(3)
α (°)	90.00	90.00
β (°)	92.3000(10)	90.00
γ (°)	90.00	90.00
<i>V</i> (Å ³)	1948.95(6)	3999.68(13)
<i>Z</i>	4	8
D _c (g/cm ³)	1.263	1.297
<i>F</i> ₀₀₀	792	1648
μ (mm ⁻¹)	0.183	1.601
θ_{\max} (°)	26.77	77.81
Total reflections	14006	15938
Unique reflections	3855	3992
Reflections [<i>I</i> > 2 σ (<i>I</i>)]	3113	3450
Parameters	237	255
<i>R</i> _{int}	0.0391	0.0275
Goodness-of-fit	1.025	1.078
<i>R</i> [<i>F</i> ² > 2 σ (<i>F</i> ²)]	0.0454	0.0407
<i>wR</i> (<i>F</i> ² , all data)	0.1362	0.1256
CCDC No.	2261351	2261352

13. References

- Preindl, J.; Chakrabarty, S.; Waser, J. Dearomatization of electron poor six-membered N-heterocycles through [3 + 2] annulation with aminocyclopropanes. *Chem. Sci.* **2017**, *8*, 7112–7118.
- Pandey, K.; Muthyala, M. K.; Choudharya, S.; Kumar, A. Imidazolium salt-supported Mukaiyama reagent: an efficient condensation reagent for amide bond formation. *RSC Adv.* **2015**, *5*, 13797–13804.
- Day, A. J.; Jenkins, T. C.; Kischkewitz, M.; Christensen, K. E.; Poole, D. L.; Donohoe, T. J. Metal and Activating Group Free C-4 Alkylation of Isoquinolines via a Temporary Dearomatization Strategy. *Org. Lett.* **2023**, *25*, 614–618. (C-4 isoquinoline).
- Solji Eom, S.; Kwon, T.; Lee, D. Y.; Park, C. H.; Kim, H. J. Copper-Mediated Three-Component Reaction for the Synthesis of N-Acylsulfonamide on DNA. *Org. Lett.* **2022**, *24*, 4881–4885. (**azide synthesis**)
- (a) Yadav, S.; Chaudhary, D.; Maurya, N. K.; Kumar, D.; Ishu, Km.; Kuram, M. R. Transfer hydrogenation of pyridinium and quinolinium species using ethanol as a hydrogen source to access saturated N-heterocycles. *Chem. Commun.* **2022**, *58*, 4255–4258.
 (b) Yang, J.; Zhao, H.; Tan, Z.; Cao, L.; Jiang, H.; Ci, C.; Dixneuf, P. H.; Zhang, M. syn-Selective Construction of fused heterocycles by Catalytic Reductive Tandem Functionalization of N-Heteroarenes. *ACS Catal.* **2021**, *11*,

9271–9278.

C Yang, J.; Zhao, H.; Tan, Z.; Cao, L.; Jiang, H.; Ci, C.; Dixneuf, P. H.; Zhang, M. syn-Selective Construction of fused heterocycles by Catalytic Reductive Tandem Functionalization of N-Heteroarenes. *ACS Catal.* **2021**, *11*, 9271–9278.

(d) Tan, Z.; Ci, C.; Yang, J.; Wu, Y.; Cao, L.; Jiang, H.; Zhang, M. Catalytic Conversion of N-Heteroaromatics to Functionalized Arylamines by Merging Hydrogen Transfer and Selective Coupling. *ACS Catal.* **2020**, *10*, 5243 – 5249.

(e) Carreon, J. R.; Mahon, K. P.; Jr.; Kelley, S. O. Thiazole Orange-Peptide Conjugates: Sensitivity of DNA Binding to Chemical Structure. *Org. Lett.* **2004**, *6*, 517 – 519.

(f) Zhou, Y.; Liu, W.; Xing, Z.; Guan, J.; Song, Z.; Peng, Y. External-photocatalyst-free visible-light-mediated aerobic oxidation and 1,4-bisfunctionalization of N-alkyl isoquinolinium salts. *Org. Chem. Front.* **2020**, *7*, 2405 –2413.

(g) Wang, G.; Hu, W.; Hu, Z.; Zhang, Y.; Yao, W.; Li, L.; Fu, Z.; Huang, W. Carbene-catalyzed aerobic oxidation of isoquinolinium salts: efficient synthesis of isoquinolinones. *Green Chem.* **2018**, *20*, 3302 –3307.

(h) Bai, L.-G.; Zhou, Y.; Zhuang, X.; Zhang, L.; Xue, J.; Lin, X.-L.; Cai, T.; Luo, Q.-L. Base-promoted aerobic oxidation of N-alkyl iminium salts derived from isoquinolines and related heterocycles. *Green Chem.* **2020**, *22*, 197 –203.

6. He, Y.; Wang, X. Synthesis of Cyclic Amidines by Iridium-Catalyzed Deoxygenative Reduction of Lactams and Tandem Reaction with Sulfonyl Azides. *Org. Lett.* **2021**, *23*, 225–230. **(3a)**.

7. Huang, Y.; Yi, W.; Sun, Q.; Zhang, L.; Yi, F. A new and facile approach to 1,2-dihydroisoquinolin-3(4H)-imines by the Cu(I)-catalyzed reaction of 2-ethynylbenzyl methanesulfonates, sulfonyl azides and amines. *RSC Adv.* **2018**, *8*, 74–79. **(5a)**.

8. Nie, Y.; Li, J.; Yan, J.; Yuan, Q.; Zhang, W. Synthesis of Chiral 2-Substituted 1,4-Benzoxazin-3-ones via Iridium Catalyzed Enantioselective Hydrogenation of Benzoxazinones. *Org. Lett.* **2021**, *23*, 5373–5377.

9. Yang, X.; Wang, L.; Hu, F.; Xu, L.; Li, S.; Li, S.-S. Redox-Triggered Switchable Synthesis of 3,4-Dihydroquinolin-2(1H)-one Derivatives via Hydride Transfer/N-Dealkylation/ N-Acylation. *Org. Lett.* **2021**, *23*, 358–364.



10. Pavletić, P.; Semeano, A.; Yano, H.; Bonifazi, A.; Giorgioni, G.; Piergentili, A.; Quaglia, W.; Sabbieti, M. G.; Agas, D.; Santoni, G.; Pallini, R.; Ricci-Vitiani, L.; Sabato, E.; Vistoli, G.; Bello, F. D. Highly Potent and Selective Dopamine D4 Receptor Antagonists Potentially Useful for the Treatment of Glioblastoma. *J. Med. Chem.* **2022**, *65*, 12124–12139.

11. Reeves, B. M.; Hepburn, H. B.; Grozavu, A.; Lindsay-Scott, P. J.; Donohoe, T. J. Transition-Metal-Free Reductive Hydroxymethylation of Isoquinolines. *Angew. Chem., Int. Ed.* **2019**, *58*, 15697– 15701.

12. Cao, V. D.; Mun, S. H.; Kim, S. H.; Kim, G. U.; Kim, H. G.; Joung, S. Synthesis of Cyclic Amidines from Quinolines by a Borane-Catalyzed Dearomatization Strategy. *Org. Lett.* **2020**, *22*, 515–519.

13. Tan, Z.; Ci, C.; Yang, J.; Wu, Y.; Cao, L.; Jiang, H.; Zhang, M. Catalytic Conversion of N-Heteroaromatics to Functionalized Arylamines by Merging Hydrogen Transfer and Selective Coupling. *ACS Catal.* **2020**, *10*, 5243–5249.



14. Copies of Spectra

Figure S-1: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **a**₁₁Figure S-2: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **a**₁₁

D:\internals 2022\...HRMS22119DEC09

12/19/2022 11:29:09 AM

HRMS22119DEC09 #22 RT: 0.16 AV: 1 SB: 10 0.87-0.94 NL: 1.78E7
 F: FTMS + c ESI Full ms [100.00-750.00]

Figure S-3 HRMS spectrum of compound **a11**Figure S-4: ¹H NMR (400 MHz, CDCl₃) spectrum of compound **a14**




Figure S-5: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **a14**

D:\internals 2022\...HRMS22112DEC33

12/12/2022 12:10:59 PM

HRMS22112DEC33 #26 RT: 0.20 AV: 1 SB: 24 0.77-0.96 NL: 1.02E7
T: FTMS + c ESI Full ms [100.00-750.00]






Figure S-6 HRMS spectrum of compound **a14**

Figure S-7: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **a17**Figure S-8: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **a17**

D:\Internals 2022\...HRMS22I26DEC08

12/26/2022 11:24:48 AM

HRMS22I26DEC08 #41 RT: 0.30 AV: 1 SB: 13 0.74-0.84 NL: 2.92E7
 T: FTMS + c ESI Full ms [100.00-750.00]




Figure S-9 HRMS spectrum of compound **a17**




Figure S-10: ¹H NMR (400 MHz, DMSO-d₆) spectrum of compound **1f**




Figure S-11: ¹³C NMR (100 MHz, DMSO-d₆) spectrum of compound **1f**




Figure S-12 HRMS spectrum of compound **1f**




Figure S-13: ^1H NMR (400 MHz, DMSO-d_6) spectrum of compound **1h**






Figure S-14: ^{13}C NMR (100 MHz, DMSO-d_6) spectrum of compound **1h**

D:\internals 2022\...HRMS22102DEC23

12/2/2022 11:51:19 AM

HRMS22102DEC23 #27 RT: 0.20 AV: 1 SB: 1 0.81 NL: 3.98E6

T: FTMS + c ESI Full ms [100.00-750.00]

Figure S-15 HRMS spectrum of compound **1h**Figure S-16: ¹H NMR (500 MHz, DMSO-d₆) spectrum of compound **1k**




Figure S-17: ^{13}C NMR (100 MHz, DMSO-d_6) spectrum of compound **1k**

D:\internals 2022\NOV22\HRMS22130NOV26

11/30/2022 11:57:36 AM

HRMS22130NOV26 #27 RT: 0.20 AV: 1 SB: 10 0.88-0.95 NL: 1.49E7
 T: FTMS + c ESI Full ms [100.00-750.00]








Figure S-18 HRMS spectrum of compound **1k**

Figure S-19: ^1H NMR (400 MHz, DMSO-d_6) spectrum of compound **1q**Figure S-20: ^{13}C NMR (100 MHz, DMSO-d_6) spectrum of compound **1q**

D:\internals 2022\...HRMS22108DEC30

12/8/2022 11:56:27 AM

HRMS22108DEC30 #24 RT: 0.18 AV: 1 SB: 1 0.77 NL: 2.36E8
T: FTMS + c ESI Full ms [100.00-750.00]Figure S-21 HRMS spectrum of compound **1q**Figure S-22: ^1H NMR (400 MHz, DMSO-d_6) spectrum of compound **1r**




Figure S-23: ¹³C NMR (100 MHz, DMSO-d₆) spectrum of compound **1r**

D:\Internals 2022...\HRMS22107DEC27

12/7/2022 11:52:27 AM

HRMS22107DEC27 #21 RT: 0.16 AV: 1 SB: 24 0.66-0.85 NL: 2.16E7

T: FTMS + c ESI Full ms [100.00-750.00]




Figure S-24 HRMS spectrum of compound **1r**




Figure S-25: ¹H NMR (400 MHz, DMSO-d₆) spectrum of compound **1t**






Figure S-26: ¹³C NMR (100 MHz, DMSO-d₆) spectrum of compound **1t**

D:\internals 2022\...HRMS22106DEC28

12/6/2022 12:05:21 PM

HRMS22106DEC28 #27 RT: 0.21 AV: 1 SB: 6 0.87-0.91 NL: 7.00E5
T: FTMS + c ESI Full ms [100.00-750.00]Figure S-27 HRMS spectrum of compound **1t**Figure S-28: ¹H NMR (400 MHz, DMSO-d₆) spectrum of compound **1v**




Figure S-29: ^{13}C NMR (100 MHz, DMSO-d_6) spectrum of compound **1v**

D:\internals 2022\...HRMS22105DEC25

12/5/2022 12:21:12 PM

HRMS22105DEC25 #24 RT: 0.18 AV: 1 SB: 1 0.85 NL: 1.31E7
 T: FTMS + c ESI Full ms [100.00-750.00]






Figure S-30 HRMS spectrum of compound **1v**

Figure S-31: ^1H NMR (400 MHz, D_2O) spectrum of compound **1w**Figure S-32: ^{13}C NMR (100 MHz, D_2O) spectrum of compound **1w**




Figure S-33: ^{19}F NMR (376 MHz, D_2O) spectrum of compound **1w**

D:\internals 2022\...HRMS22101DEC24

12/1/2022 11:53:16 AM

HRMS22101DEC24 #29 RT: 0.22 AV: 1 SB: 12 0.74-0.82 NL: 1.57E7

T: FTMS + c ESI Full ms [100.00-750.00]








Figure S-34 HRMS spectrum of compound **1w**

Figure S-35: ^1H NMR (400 MHz, MeOH- d_4) spectrum of compound **1y**Figure S-36: ^{13}C NMR (100 MHz, MeOH- d_4) spectrum of compound **1y**

D:\internals 2022\...HRMS22119DEC10

12/19/2022 11:31:06 AM

HRMS22119DEC10 #25 RT: 0.19 AV: 1 SB: 11 0.87-0.95 NL: 2.02E7
 T: FTMS + c ESI Full ms [100.00-750.00]

Figure S-37 HRMS spectrum of compound **1y**Figure S-38: ¹H NMR (400 MHz, MeOH-d₄) spectrum of compound **1z**




Figure S-39: ^{13}C NMR (100 MHz, MeOH- d_4) spectrum of compound **1z**

D:\internals 2022\...HRMS22112DEC34

12/12/2022 12:12:56 PM

HRMS22112DEC34 #26 RT: 0.19 AV: 1 SB: 24 0.77-0.96 NL: 1.74E7
 T: FTMS + c ESI Full ms [100.00-750.00]








Figure S-40 HRMS spectrum of compound **1z**

Figure S-41: ¹H NMR (400 MHz, DMSO-d₆) spectrum of compound **4f**Figure S-42: ¹³C NMR (100 MHz, DMSO-d₆) spectrum of compound **4f**

D:\internals 2022\...HRMS22109DEC32

12/9/2022 1:14:58 PM

HRMS22109DEC32 #26 RT: 0.20 AV: 1 SB: 1 0.68 NL: 1.24E7
 T: FTMS + c ESI Full ms [100.00-750.00]

Figure S-43 HRMS spectrum of compound **4f**Figure S-44: ^1H NMR (400 MHz, DMSO-d_6) spectrum of compound **4g**




Figure S-45: ¹³C NMR (100 MHz, DMSO-d₆) spectrum of compound **4g**

D:\INTERNAL 2023\JAN 2023\HRMS23116JAN29

1/16/2023 12:08:35 PM

HRMS23116JAN29 #17 RT: 0.13 AV: 1 SB: 16 0.17-0.20 , 0.47-0.55 NL: 7.66E6
T: FTMS + c ESI Full ms [100.00-750.00]




Figure S-46 HRMS spectrum of compound **4g**




Figure S-47: ¹H NMR (400 MHz, DMSO-d₆) spectrum of compound **4h**






Figure S-48: ¹³C NMR (125 MHz, DMSO-d₆) spectrum of compound **4h**

D:\internals 2022\...HRMS22109DEC31

12/9/2022 1:12:57 PM

HRMS22109DEC31 #15-31 RT: 0.11-0.23 AV: 17 SB: 11 0.83-0.92 NL: 7.81E6
T: FTMS + c ESI Full ms [100.00-750.00]Figure S-49 HRMS spectrum of compound **4h**Figure S-50: ¹H NMR (400 MHz, DMSO-d₆) spectrum of compound **4n**




Figure S-51: ^{13}C NMR (100 MHz, DMSO-d_6) spectrum of compound **4n**

D:\INTERNAL 2023\FEB 2023\HRMS23I02FEB26

2/2/2023 11:47:26 AM

HRMS23I02FEB26 #33 RT: 0.27 AV: 1 SB: 1 0.75 NL: 1.35E5
 T: FTMS + c ESI Full ms [100.00-750.00]






Figure S-52 HRMS spectrum of compound **4n**

Figure S-53: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **3a**Figure S-54: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **3a**











Figure S-55 HRMS spectrum of compound 3a

Figure S-56: ^1H NMR (400 MHz, $\text{CD}_3\text{OD}+\text{CDCl}_3$) spectrum of compound 3b

Figure S-57: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **3b**Figure S-58 HRMS spectrum of compound **3b**

Figure S-59: ¹H NMR (400 MHz, CDCl₃) spectrum of compound **3c**Figure S-60: ¹³C NMR (100 MHz, CDCl₃) spectrum of compound **3c**

Figure S-61 HRMS spectrum of compound **3c**Figure S-62: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **3d**




Figure S-63: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **3d**














Figure S-64 HRMS spectrum of compound **3d**

Figure S-65: ¹H NMR (500 MHz, CDCl₃) spectrum of compound **3e**Figure S-66: ¹³C NMR (125 MHz, CDCl₃) spectrum of compound **3e**

Figure S-67 HRMS spectrum of compound **3e**Figure S-68: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **3f**

Figure S-69: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **3f**Figure S-70 HRMS spectrum of compound **3f**

Figure S-71: ¹H NMR (400 MHz, CDCl₃) spectrum of compound **3g**Figure S-72: ¹³C NMR (100 MHz, CDCl₃) spectrum of compound **3g**

Figure S-73 HRMS spectrum of compound **3g**Figure S-74: ^1H NMR (400 MHz, DMSO-d_6) spectrum of compound **3h**




Figure S-75: ^{13}C NMR (100 MHz, DMSO-d_6) spectrum of compound **3h**








Figure S-76 HRMS spectrum of compound **3h**

Figure S-77: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **3i**Figure S-78: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **3i**

Figure S-79 HRMS spectrum of compound **3i**Figure S-80: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **3j**




Figure S-81: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **3j**








Figure S-82 HRMS spectrum of compound **3j**

Figure S-83: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **3k**Figure S-84: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **3k**

Figure S-85 HRMS spectrum of compound **3k**Figure S-86: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **3a''**




Figure S-87: ¹³C NMR (125 MHz, CDCl₃) spectrum of compound **3a''**






Figure S-88 HRMS spectrum of compound **3a''**

Figure S-89: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **3m**Figure S-90: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **3m**





Figure S-90 HRMS spectrum of compound 3m

Figure S-91: ^1H NMR (400 MHz, CDCl_3) spectrum of compound 3m'




Figure S-92: ¹³C NMR (100 MHz, CDCl₃) spectrum of compound **3m'**

D:\INTERNAL 2023\FEB 2023\HRMS23102\FEB27

2/2/2023 11:49:23 AM

HRMS23102\FEB27 #35 RT: 0.27 AV: 1 SB: 1 0.76 NL: 2.91E6

T: FTMS + c ESI Full ms [100.00-750.00]




Figure S-93 HRMS spectrum of compound **3m'**




Figure S-94: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **3p**






Figure S-95: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **3p**

Figure S-96 HRMS spectrum of compound **3p**Figure S-97: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **3q**







Figure S-98: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 3q

Figure S-99 HRMS spectrum of compound 3q

Figure S-100: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **3r**Figure S-101: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **3r**

Figure S-102 HRMS spectrum of compound **3r**Figure S-103: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **3s**




Figure S-104: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **3s**








Figure S-105 HRMS spectrum of compound **3s**

Figure S-106: ¹H NMR (500 MHz, CDCl₃) spectrum of compound **3t**Figure S-107: ¹³C NMR (125 MHz, CDCl₃) spectrum of compound **3t**

Figure S-108 HRMS spectrum of compound **3t**Figure S-109: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **3u**




Figure S-110: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **3u**








Figure S-111 HRMS spectrum of compound **3u**

Figure S-112: ¹H NMR (400 MHz, CDCl₃) spectrum of compound **3v**Figure S-113: ¹³C NMR (100 MHz, CDCl₃) spectrum of compound **3v**

Figure S-114 HRMS spectrum of compound **3v**Figure S-115: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **3w**




Figure S-116: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **3w**






Figure S-117: ^{19}F NMR (376 MHz, CDCl_3) spectrum of compound **3w**

Figure S-118 HRMS spectrum of compound **3w**Figure S-119: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **3x**




Figure S-120: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **3x**






Figure S-121 HRMS spectrum of compound **3x**

Figure S-122: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **3y**Figure S-123: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **3y**

Sample Name DC-05 Position Vial 27 Instrument Name Instrument 1 User Name
 Inj Vol 1 InjPosition SampleType Sample IRM Calibration Status Some Ions Missed
 Data Filename HRMS22I30AUG27.d ACQ Method ISOCRATIC.m Comment Acquired Time 8/30/2022 12:39:24 PM




Figure S-124 HRMS spectrum of compound **3y**




Figure S-125: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **3z**




Figure S-126: ¹³C NMR (125 MHz, CDCl₃) spectrum of compound **3z**








Figure S-127 HRMS spectrum of compound **3z**

Figure S-128: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **5a**Figure S-129: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **5a**

Figure S-130 HRMS spectrum of compound **5a**Figure S-131: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **5b**




Figure S-132: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **5b**

D:\INTERNALS 2022\...HRMS22113SEP24

9/13/2022 12:26:30 PM

DC-02-393

HRMS22113SEP24 #43 RT: 0.33 AV: 1 SB: 8 0.02-0.08 NL: 1.19E6
T: FTMS + c ESI Full ms [100.00-750.00]






Figure S-133 HRMS spectrum of compound **5b**

Figure S-134: ¹H NMR (400 MHz, CDCl₃) spectrum of compound **5c**Figure S-135: ¹³C NMR (100 MHz, CDCl₃) spectrum of compound **5c**

D:\INTERNAL 2023\JAN 2023\HRMS2312\JAN30

1/12/2023 11:59:22 AM

HRMS2312\JAN30 #23 RT: 0.18 AV: 1 SB: 19 0.79-0.95 NL: 8.92E5
 T: FTMS + c ESI Full ms [100.00-750.00]





Figure S-136 HRMS spectrum of compound 5c

Figure S-137: ¹H NMR (500 MHz, CDCl₃) spectrum of compound 5d




Figure S-138: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **5d**

D:\INTERNALS 2022\...\HRMS22114SEP19

9/14/2022 11:35:58 AM

KMR-02

HRMS22114SEP19 #24 RT: 0.18 AV: 1 SB: 8 0.02-0.08 NL: 5.10E5

T: FTMS + c ESI Full ms [100.00-750.00]








Figure S-139 HRMS spectrum of compound **5d**

Figure S-140: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **5e**Figure S-141: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **5e**

D:\internals 2022\NOV22\HRMS22\30NOV25

11/30/2022 11:55:42 AM

HRMS22\30NOV25 #26 RT: 0.20 AV: 1 SB: 1 0.76 NL: 1.26E6
T: FTMS + c ESI Full ms [100.00-750.00]Figure S-142 HRMS spectrum of compound **5e**Figure S-143: ¹H NMR (500 MHz, CDCl₃) spectrum of compound **5f**




Figure S-144: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **5f**

D:\internals 2022\NOV22\HRMS22128\NOV17

11/28/2022 12:08:52 PM

HRMS22128NOV17 #26 RT: 0.20 AV: 1 SB: 9 0.65-0.72 NL: 2.46E6

T: FTMS + c ESI Full ms [100.00-750.00]




Figure S-145 HRMS spectrum of compound **5f**




Figure S-146: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **5g**






Figure S-147: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **5g**

Figure S-148 HRMS spectrum of compound **5g**Figure S-149: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **5h**




Figure S-150: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **5h**

D:\INTERNALS 2022\...HRMS22115SEP18

9/15/2022 11:26:09 AM

KMR-02-

HRMS22115SEP18 #27 RT: 0.21 AV: 1 SB: 7 0.02-0.07 NL: 4.58E5
 T: FTMS + c ESI Full ms [100.00-750.00]









Figure S-151 HRMS spectrum of compound **5h**

Figure S-152: ¹H NMR (400 MHz, CDCl₃) spectrum of compound **5i**Figure S-153: ¹³C NMR (125 MHz, CDCl₃) spectrum of compound **5i**


Figure S-154 HRMS spectrum of compound **5i**Figure S-155: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **5j**



Figure S-156: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **5j**



D:\INTERNALS 2022\...HRMS22115SEP17

9/15/2022 11:24:13 AM

DC-14

HRMS22115SEP17 #17 RT: 0.13 AV: 1 SB: 8 0.02-0.08 NL: 2.03E6
 T: FTMS + c ESI Full ms [100.00-750.00]Figure S-157 HRMS spectrum of compound **5j**

Figure S-158: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **5k**Figure S-159: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **5k**

Figure S-160 HRMS spectrum of compound **5k**Figure S-161: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **5l**





Figure S-162: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 5I



Figure S-163 HRMS spectrum of compound 5I

Figure S-164: ¹H NMR (500 MHz, CDCl₃) spectrum of compound **5m**Figure S-165: ¹³C NMR (125 MHz, CDCl₃) spectrum of compound **5m**

D:\INTERNALS 2022\...HRMS22114SEP20

9/14/2022 11:37:53 AM

SD-01-791

HRMS22114SEP20 #30 RT: 0.23 AV: 1 SB: 8 0.02-0.08 NL: 1.60E6
T: FTMS + c ESI Full ms [100.00-750.00]Figure S-166 HRMS spectrum of compound **5m**Figure S-167: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **5n**




Figure S-168: ¹³C NMR (125 MHz, CDCl₃) spectrum of compound **5n**

D:\INTERNAL 2023\FEB 2023\HRMS23103FEB26

2/3/2023 11:59:07 AM

HRMS23103FEB26 #22 RT: 0.18 AV: 1 SB: 1 0.77 NL: 2.26E5
 T: FTMS + c ESI Full ms [100.00-750.00]






Figure S-169 HRMS spectrum of compound **5n**

Figure S-170: ¹H NMR (500 MHz, CDCl₃) spectrum of compound **5o**Figure S-171: ¹³C NMR (125 MHz, CDCl₃) spectrum of compound **5o**

D:\internals 2022\NOV22\HRMS22124NOV31

11/24/2022 12:10:53 PM



HRMS22124NOV31 #17 RT: 0.12 AV: 1 SB: 1 0.51 NL: 1.31E6
T: FTMS + c ESI Full ms [100.00-750.00]

Figure S-172 HRMS spectrum of compound 5o

Figure S-173: ¹H NMR (400 MHz, CDCl₃) spectrum of compound 5p




Figure S-174: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **5p**

D:\internals 2022\NOV22\HRMS22\29NOV24

11/29/2022 12:07:00 PM

HRMS22\29NOV24 #18 RT: 0.14 AV: 1 NL: 3.77E6
 T: FTMS + c ESI Full ms [100.00-750.00]






Figure S-175 HRMS spectrum of compound **5p**

Figure S-176: ¹H NMR (400 MHz, CDCl₃) spectrum of compound **5q**Figure S-177: ¹³C NMR (100 MHz, CDCl₃) spectrum of compound **5q**

D:\internals 2022\...HRMS22101DEC23

12/1/2022 11:51:20 AM



HRMS22101DEC23 #25 RT: 0.19 AV: 1 SB: 13 0.87-0.96 NL: 5.88E6
T: FTMS + c ESI Full ms [100.00-750.00]

Figure S-178 HRMS spectrum of compound 5q

Figure S-179: ¹H NMR (400 MHz, CDCl₃) spectrum of compound 5r




Figure S-180: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 5r

D:\internals 2022\NOV22\HRMS22I28NOV18

11/28/2022 12:10:49 PM

HRMS22I28NOV18 #26 RT: 0.20 AV: 1 SB: 9 0.64-0.71 NL: 6.66E6

T: FTMS + c ESI Full ms [100.00-750.00]








Figure S-181 HRMS spectrum of compound 5r

Figure S-182: ¹H NMR (400 MHz, CDCl₃) spectrum of compound **5s**Figure S-183: ¹³C NMR (100 MHz, CDCl₃) spectrum of compound **5s**

D:\internals 2022\NOV22\HRMS22124NOV32

11/24/2022 12:12:50 PM

HRMS22124NOV32 #26 RT: 0.19 AV: 1 SB: 1 0.51 NL: 6.11E6
T: FTMS + c ESI Full ms [100.00-750.00]Figure S-184 HRMS spectrum of compound **5s**Figure S-185: ¹H NMR (500 MHz, CDCl₃) spectrum of compound **5t**




Figure S-186: ¹³C NMR (125 MHz, CDCl₃) spectrum of compound 5t

D:\Internals 2022\...HRMS22102DEC24

12/2/2022 11:53:14 AM

HRMS22102DEC24 #21 RT: 0.16 AV: 1 SB: 10 0.64-0.71 NL: 8.18E5
 T: FTMS + c ESI Full ms [100.00-750.00]








Figure S-187 HRMS spectrum of compound 5t

Figure S-188: ^1H NMR (500 MHz, CDCl_3) spectrum of compound **5u**Figure S-189: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **5u**

D:\internals 2022\NOV22\HRMS22I30NOV19

11/30/2022 11:44:01 AM

HRMS22I30NOV19 #30 RT: 0.22 AV: 1 SB: 1 0.69 NL: 4.97E6
T: FTMS + c ESI Full ms [100.00-750.00]Figure S-190 HRMS spectrum of compound **5u**Figure S-191: ¹H NMR (500 MHz, CDCl₃) spectrum of compound **6a**




Figure S-192: ¹³C NMR (125 MHz, CDCl₃) spectrum of compound **6a**

D:\INTERNALS 2022\...HRMS22116SEP19

9/16/2022 12:03:00 PM

SY-02-78-2

HRMS22116SEP19 #26 RT: 0.20 AV: 1 SB: 7 0.02-0.07 NL: 1.37E6

T: FTMS + c ESI Full ms [100.00-750.00]






Figure S-193 HRMS spectrum of compound **6a**

Figure S-194: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **6w**Figure S-195: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **6w**




Figure S-196: ^{19}F NMR (376 MHz, CDCl_3) spectrum of compound **6w**

D:\internals 2022\...HRMS22115DEC10

12/15/2022 11:21:30 AM

HRMS22115DEC10 #21 RT: 0.16 AV: 1 SB: 18 0.63-0.77 NL: 8.86E5
T: FTMS + c ESI Full ms [100.00-750.00]








Figure S-197 HRMS spectrum of compound **6w**

Figure S-198: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **8**Figure S-199: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **8**

D:\INTERNAL 2023\JAN 2023\HRMS23106JAN11

1/6/2023 11:26:52 AM

HRMS23106JAN11 #31 RT: 0.24 AV: 1 SB: 24 0.74-0.93 NL: 6.20E5
T: FTMS + c ESI Full ms [100.00-750.00]Figure S-200 HRMS spectrum of compound **8**Figure S-201: ¹H NMR (400 MHz, CDCl₃) spectrum of compound **9**




Figure S-202: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound 9








Figure S-203 HRMS spectrum of compound 9

Figure S-204: ^1H NMR (500 MHz, CDCl_3) spectrum of compound 10Figure S-205: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 10

D:\internals 2022\...HRMS22127DEC14

12/27/2022 11:50:44 AM

HRMS22127DEC14 #20 RT: 0.15 AV: 1 NL: 4.54E6
T: FTMS + c ESI Full ms [100.00-750.00]Figure S-206 HRMS spectrum of compound **10**Figure S-207: ¹H NMR (500 MHz, CDCl₃) spectrum of compound **6e**




Figure S-208: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound **6e**

D:\internals 2022\...HRMS22119OCT31

10/19/2022 1:04:56 PM

HRMS22119OCT31 #23 RT: 0.18 AV: 1 NL: 4.54E5
 T: FTMS + c ESI Full ms [100.00-750.00]









Figure S-209 HRMS spectrum of compound **6e**

Figure S-210: ^1H NMR (400 MHz, CDCl_3) spectrum of compound 14Figure S-211: ^{13}C NMR (125 MHz, CDCl_3) spectrum of compound 14

D:\internals 2022\...HRMS22119OCT32

10/19/2022 1:06:53 PM

HRMS22119OCT32 #26 RT: 0.20 AV: 1 NL: 1.50E6
T: FTMS + c ESI Full ms [100.00-750.00]Figure S-212 HRMS spectrum of compound **14**Figure S-213: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **16**

Figure S-214: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound 16

D:\INTERNAL 2023\JAN 2023\HRMS23112\JAN17

1/12/2023 11:34:04 AM





HRMS23112JAN17 #21 RT: 0.16 AV: 1 NL: 1.15E6
T: FTMS + c ESI Full ms [100.00-750.00]

Figure S-215 HRMS spectrum of compound 16

Figure S-216: ^1H NMR (400 MHz, CDCl_3) spectrum of compound **18**Figure S-217: ^{13}C NMR (100 MHz, CDCl_3) spectrum of compound **18**

D:\INTERNAL 2023\JAN 2023\HRMS23I19JAN14

1/19/2023 3:23:52 PM

HRMS23I19JAN14 #16 RT: 0.12 AV: 1 SB: 1 0.89 NL: 6.01E6
T: FTMS + c ESI Full ms [100.00-750.00]Figure S-218 HRMS spectrum of compound **18**